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 Fair balance of benefit and risk information in consumer prescription drug advertising 
(DTCA) has received much research attention. In this regard, it has been well-documented that 
varying levels of risk disclosure prominence have disproportional effects on consumer response 
to the DTC ad. However, little research has examined how the prominence effects can be 
maximized or minimized depending on consumers’ varying levels of knowledge of the FDA’s 
regulatory role for DTCA. In a similar vein, rare research has been conducted to investigate how 
such regulatory knowledge directly affects consumers’ risk disclosure coping strategies. 
Drawing on consumer information processing perspectives, this research employs an 
experimental approach to examine one manipulated categorical variable, one measured 
continuous variable, and their interactive effects on consumer response to the ad, while 
controlling for potential covariates. Specifically, two levels of risk disclosure prominence are 
manipulated (high vs. low) and coded as a dummy variable, and DTCA regulatory knowledge is 
measured as a continuous variable. Further, based on the persuasion knowledge model (PKM) 
framework, DTCA regulatory knowledge is tested as a moderator of the prominence effects. 
Consumer memory such as unaided-recall and aided-recognition of the health risks of the 
medicine presented in the ad as well as self-reported perceived attention to risk disclosure are 
addressed as criterion variables. 
The major findings are summarized as follows: (1) both higher DTCA regulatory 
knowledge and higher prominence enhanced perceived attention to risk disclosure; (2) both 
higher DTCA regulatory knowledge and higher prominence enhanced consumer recognition of 





perceived attention to risk disclosure; (4) the main DTCA regulatory knowledge effects and the 
main prominence effects on consumer recall and recognition were mediated through perceived 
attention to risk disclosure; (5) However, the moderated mediation effect analyses revealed that 
the effects of prominence on recall and recognition were mediated through perceived attention 
among low DTCA regulatory knowledge consumers, whereas the mediating effects were 
minimal among high DTCA regulatory knowledge consumers. 
The overall findings support the current study’s conceptual framework. The theoretical, 
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CHAPTER 1: INTRODUCTION 
Research Problem 
 Given that today’s health care patients are increasingly referred to as consumers (Hibbard 
& Weeks, 1987; Tomes, 2006), health care consumerism is defined as consumers’ autonomy in 
their health care management (Hibbard & Weeks, 1987). In this regard, Almond (2001) suggests 
that the terms partnership and participation are regarded as appropriate labels for the consumer-
oriented contemporary health care context. In order to achieve sound healthcare partnership 
participation, consumers must be provided with accurate and comprehensive health information 
to make informed health choices, including information about available medical remedies and 
their potential health risks. Direct-to-consumer prescription drug advertising (DTCA) represents 
one important health information source (Royne & Myers, 2008; Macias, Pashupati, & Lewis, 
2007; Macias, Lewis, & Baek, 2010), and therefore it is critical to consider how consumers’ 
perception regarding health issues are influenced by DTCA health information (Park, Ju, & Kim, 
2013; Ju & Park, 2013).  
However, despite the presumed importance of DTCA, the literature has found that most 
DTC ads tend to present information about the uses and efficacy of the medicine more 
prominently than its possible health risks (e.g., Avery, Eisenberg, & Simon, 2012; Davis, Cross, 
& Crowley, 2007; Davis & Meader, 2009; Huh & Cude, 2004; Kaphingst, Dejong, Rudd, & 
Daltroy, 2004; Macias et al., 2007; Macias et al., 2010; Sheehan, 2007). In line with this finding, 
the Federal Food, Drug, and Cosmetic Act (hereinafter, FFD&C Act; 21 U.S.C. 352) requires 
pharmaceutical advertisers to present any word, statement, or other information prominently to 





purchase and use. Especially, regarding important health risk information in DTC ads, 
pharmaceutical advertisers are obligated to prominently provide risk disclosure to be comparable 
with benefit and use information in their promotional materials, a policy commonly referred to as 
the fair balance requirement (21 Code of Federal Regulation 202.1; hereinafter, 21 CFR 202.1).  
The FDA (2009) provides specific guidance to pharmaceutical advertisers regarding how 
they must present important health risks of the medicine in DTCA. For instance, risk information 
prominence is considered an important aspect, and it could consist of various message execution 
factors such as typography, layout, contrast, headlines, paragraphing, white space, and other 
techniques used to achieve emphasis (US Department of Health and Human Services [DHHS], 
2010). However, little research has empirically examined how the effects of such message 
execution factors can be influenced by consumer characteristics (Davis, 2010; Macias et al., 
2007; Sheehan, 2007). This limitation in the literature poses a necessity to investigate how the 
risk disclosure prominence effects on consumer response to the DTC ad can be affected by 
individual differences in consumer characteristics. That is, understanding in which situations the 
effects could be enhanced or diluted, and in what mechanisms the effects operate remain as 
understudied areas. 
Furthermore, the direct effects of consumer characteristics on consumer response to the 
DTC ad have also been rarely examined. To address this void in the DTCA literature, the current 
research addresses the direct effects of DTCA regulatory knowledge, its moderating role of the 
risk disclosure prominence effects, along with the direct effects of risk disclosure prominence on 
consumer response to the DTC ad. To do so, the current research borrows from the persuasion 





regulatory knowledge, and draws on the FDA’s (2009) conceptualization of risk disclosure 
prominence to test the effects of varying levels of risk disclosure prominence. 
 Although a body of DTCA research has examined the content of DTC ads in terms of fair 
balance between benefit and risk information, most of the studies have exclusively relied on 
descriptive content analysis to determine the relative quantity of risk information compared to 
benefit information (Davis, 2010; Davis & Meader, 2009; Huh & Cude, 2004; Macias et al., 
2007, 2010). However, to better understand the dynamic consumer information processing of 
DTCA risk disclosure, one needs to examine under which conditions consumers could benefit 
from risk disclosure provision more or less (Harker & Harker, 2007).  
Research has rarely examined how consumer’s cognitive factors affect their information 
processing of risk disclosure. Consumers’ knowledge of the FDA’s regulatory role for DTCA 
may be one critical variable that has not been explored in terms of consumers’ DTCA risk 
disclosure coping strategies. Given that it has been well-documented that consumers’ cognitive 
structure such as marketplace knowledge or beliefs may exert considerable influence on 
consumers’ persuasive message coping strategies (Boush, Friestad, & Wright, 2009; Friestad & 
Wright, 1994; Obermiller & Spangenberg, 1998; Obermiller, Spangenberg, & MacLachlan, 
2005), the lack of research addressing this perspective in the DTCA literature is undesirable. 
Additionally, little research has explored a psychological mechanism whereby DTCA 
regulatory knowledge, DTCA risk disclosure prominence, and their interplay may influence 
recall and recognition of risk information. Although we know that in general enhanced cognitive 
fluency may improve information processing outcomes (e.g., Alba & Hutchinson, 1987; Kardes, 





convincing evidence regarding the process in the DTCA context. By revealing the black box in 
consumers’ risk disclosure processing mechanism, those involved in DTCA will benefit from the 
current study’s findings. 
 
Purpose of the Study 
 The prescription drug industry is considered a high consequence area that affects public 
health considerably. A number of consumer researchers have voiced that the examination of 
DTCA impact on consumers should be based on observation of consumers' actual response to 
DTCA (e.g., Beltramini, 2010; Hoek, Gendall, Rapson, & Louviere, 2011; Kavadas, Katsanis, & 
LeBel, 2007; Myers, Royne, & Deitz, 2011). Such consumer-oriented approach will provide 
insight into how to better encourage consumers to process information about the benefits and 
risks of the drug in a balanced manner. Further, the approach will offer useful guidance for the 
development of effective risk disclosure communication and consumer education program by the 
FDA and pharmaceutical marketers, which have been underexplored in the literature. 
 From consumer education and public health perspectives, effective health risk 
information provision through DTCA has an important implication. Considering that consumers' 
sound health decisions hinge largely upon their appropriate use of health information, the current 
research will elucidate how risk disclosure in DTCA can be more effectively presented in order 
to enhance consumers’ cognitive memory performance regarding risk information in the ad.  
It is worth noting that, during the last decades, the FDA’s DTCA public policy has 
shifted its focus from DTCA content per se to consumers’ actual perception about the promoted 





examined consumer perception such as general attitudes toward DTCA (e.g., Sumpradit, 
Ascione, & Bagozzi, 2004) and preferences for communicating risk information (Davis, 2007), 
how consumers’ cognitive knowledge structure can affect the dynamic mechanism of risk 
disclosure coping strategies has received little research attention to date. By addressing this gap 
in the literature, consumer educators, pharmaceutical marketers, and health communication 
researchers will benefit from the current research’s findings. 
Specifically, the current research attempts to examine the effects of consumer knowledge 
of the FDA’s regulatory role for DTCA (hereinafter, DTCA regulatory knowledge), risk 
disclosure prominence, and their interplay on consumer response to the DTC ad, including 
perceived attention to, recall, and recognition of risk information in the DTC ad. Based on the 
PKM perspective, DTCA regulatory knowledge is viewed as one type of crucial pharmaceutical 
marketplace belief. Depending on varying levels of DTCA regulatory knowledge, consumers’ 
risk information processing outcomes using DTCA may largely vary. 
The additional purpose of the present study is to investigate how the effects of DTCA 
regulatory knowledge, risk disclosure prominence, and their interaction on consumers’ memory 
of the drug’s potential health risks presented in the ad are mediated by perceived attention to risk 
information in the ad. Considering that perceived attention represents one type of proxy measure 
for consumer attention, perceived ease with locating disclosure in DTCA is expected to mediate 
the effects of DTCA regulatory knowledge, disclosure prominence, and their interaction on 
consumers’ cognitive memory performance, including the extent of recall and recognition of 
health risk information (Bettman, Payne, & Staelin, 1986). Illuminating this under-examined 





and how consumers’ marketplace persuasion knowledge can contribute to public health. 
 
The Organization of Dissertation 
 This dissertation is organized as follows. The next chapter presents a brief introduction to 
the DTCA context. The chapter introduces the controversy over DTCA and the DTCA market in 
the US context. Then, previous research on DTCA and the fair balance requirement with a focus 
on risk disclosure are reviewed in order to provide a foundation for the research phenomenon of 
this dissertation.  
The next section addresses the importance of examining consumer information 
processing in regard to DTCA risk disclosure. In the same chapter, based on the review of 
literature, the research framework of this dissertation is introduced for examining DTCA 
regulatory knowledge as a consumer factor and DTCA risk disclosure prominence as a message-
side factor. In addition, the interactive relationship between DTCA regulatory knowledge and 
risk disclosure prominence is addressed, along with the mediating role of perceived attention. By 
doing so, this chapter extends prior research on DTCA risk disclosure and the PKM perspective. 
Then, this chapter elaborates more on the FDA’s conceptualization of risk disclosure prominence 
in DTCA to operationalize prominence in the experiment of current research. Based on the 
review of literature, this chapter develops the research hypotheses. 
 The third chapter addresses the method of this research with justification. Using an 
experimental approach, risk disclosure prominence is manipulated and tested as an independent 
variable, and DTCA regulatory knowledge is measured and tested as not only an independent 





Criterion variables’ measures of this research include consumers’ perceived attention to, recall 
of, and recognition of risk information. Perceived attention is conceptualized and measured as a 
self-reported indicator to represent a proxy measure of consumers’ subjective attention. Recall 
and recognition are measured to assess objective cognitive task performance to complement the 
subjective self-report measure. Finally, potential covariates of the criterion variables are 
identified from the health communication literature and controlled to exclude potential 
confounding influences on the outcome variables. 
 The fourth chapter provides information about the analytical approach with justification 
and the findings of this research. In this chapter, a set of multiple hierarchical regressions are 
employed to test the main effects of DTCA regulatory knowledge and risk disclosure 
prominence along with their interactive effects, as developed in the literature review chapter. In 
addition, adopting a widely utilized approach to pinpoint the interaction pattern for regression 
equations, the slopes and intercepts of the regression equations (for each subgroup: high and low 
prominence) of this research are interpreted to see if the interactive patterns between DTCA 
regulatory knowledge and risk disclosure prominence are consistent with the hypothesized ones. 
Finally, a bootstrap approach, a contemporary method for mediation analysis, is employed to 
examine the hypothesized mediating role of perceived attention. 
 The fifth chapter draws upon the results and discusses meaningful findings regarding the 
effects of DTCA regulatory knowledge, risk disclosure prominence, their interaction, and the 
mediating effects of perceived attention. The theoretical, managerial, and consumer 
education/public health implications of the research are addressed. The final chapter addresses 





CHAPTER 2: LITERATURE REVIEW 
The DTCA Market 
DTCA refers to the prescription drug ads that are published in magazines and newspapers 
distributed to general consumers, and electronic media such as TV, radio, and the Internet are 
also considered important platforms for DTCA (FDA, 2014a). Since the early 1990s when some 
drug manufacturers began targeting consumers, DTCA has been one of the most widely utilized 
health information sources (FDA, 2014a). In particular, after the restrictions on the DTCA 
regulations were relaxed in 1997, its marketing expenditure has rapidly increased to be the 
second largest consumer advertising category during the period of 2007-2008 (Nielsen, 2009). 
More specifically, the DTCA spending of TV, radio, magazines, newspapers, and 
outdoor, reached $4.9 billion in 2007 (Hilsenrath, 2011). Although it decreased to $4.3 billion in 
2009 (Kaiser Family Foundation, 2010), to $4.0 billion in 2010, and to $3.9 billion in 2011 (IMS 
Health, 2011), after the severe US economic recession of 2007-2008, the recent DTCA 
expenditure reportedly turned to increase again. Further, when considering the growth potential 
of Internet and mobile media DTCA, this advertising category will continue to grow for the 
meantime. As a matter of fact, pharmaceutical marketers are increasingly embracing the Internet 
as a promotional medium (Dutta-Bergman, 2004; Wymer, 2010). Online DTCA expenditure 
alone is estimated to reach $1.3 billion by 2008 (Oser, 2006).  
Today, the average American TV viewer watches as many as nine drug ads a day and 
approximately 91% of Americans report that they are aware of the DTCA category (Myers, 
Royne, & Deitz, 2011; Ventola, 2011). In the same token, those who watch average amounts of 





Eisenberg, & Simon, 2012). Overall, given its amount of advertising spending and consumer 
exposure to it, DTCA is considered a major consumer advertising category in the US consumer 
media market (An & Muturi, 2011; Matear & Dacin, 2010; Royne & Myers, 2008; Tsai & 
Lancaster, 2012; van de Pol & de Bakker, 2010). 
 
The Context of DTCA 
 The early DTCA appeared in the US mass media in the 1980s though it has become a 
popular promotional tool since the early 1990s (FDA, 2014a). At first, it was almost impossible 
for pharmaceutical advertisers to meet the FDA’s strict requirements for information provision 
due to the limitations of time in broadcast media, and therefore DTCA has been rarely 
implemented in electronic media until the FDA’s relaxation of its regulations over DTCA in 
television in 1997 (An & Kang, 2011). 
Only two countries in the world allow DTCA due to its potential harmful consequences 
on public health (Royne & Meyer, 2008): the US and New Zealand. In the US, prescription drug 
advertising was allowed only to health care professionals in the past, based on the belief that the 
general public would be less capable of understanding information about the uses and risks of 
medical remedies (Macias & Lewis, 2004). However, the contemporary healthcare system and 
communities have shifted to encourage the partnership between patients and health professionals 
(Almond, 2001; Tomes, 2006). One of the drivers of this change may include consumers’ 
increased motivation for seeking health information and well-being. In addition, due to the 
advance of media technologies including the Internet and portable communication devices, 





context, DTCA is considered one of such important health information sources. 
Over the past few decades, however, DTCA has raised a severe controversy among its 
stakeholders. The proponents and opponents of DTCA have insisted on their own point of views, 
and research findings regarding the influence of DTCA on consumers remain mixed (Royne & 
Myers, 2008). DTCA proponents maintain that DTCA appears to drive conversation about 
possible medical treatment options between the patient and their physician (Auton, 2007) as well 
as remind the patient who already has been prescribed medicines to take them. From the 
proponents’ perspective, DTCA is expected to provide current and potential patients with useful 
health information that help them make informed health decisions (Royne & Myers, 2008).  
Another alleged contribution of DTCA to public health is its capability to help people 
recognize whether they may contract a certain disease that would otherwise remain unidentified 
and untreated (Donohue & Berndt, 2004; Peyrot, Alperstein, Van Doren, & Poli, 1998; Roth, 
1996). Advocates also argue that DTCA empowers patients to take a more active role in their 
health care management (Holmer, 1999) and reduces the stigma associated with treatment of 
certain health conditions such as clinical depression (An & Kang, 2011). Overall, proponents’ 
contention can be summarized as DTCA’s educational contribution to informed health decisions 
and public health promotion in the long run (An & Muturi, 2011; Royne & Myers, 2008). 
Advocates also point out that excessive regulations on DTCA may violate the freedom of speech 
clause in the First Amendment (Grenard, Uy, Pagan, & Frosch, 2011). 
 In contrast, opponents maintain that DTCA tends to drive consumers’ unnecessary use of 
medicines and urge them to spend on expensive branded drugs while steering them away from 





relationship between the patient and their physician may deteriorates due to DTCA’s prompting 
of patients’ disobedience and inappropriate prescription request (Rosenthal & Donohue, 2005). 
In this regard, physicians have expressed a concern that patients’ inappropriate prescription 
request often disturbs physician-patient conversation because they need to spend much time 
correcting consumers’ misunderstanding obtained from DTCA (Harker & Harker, 2007; Royne 
& Myers, 2008). Moreover, dissenters assert that information conveyed in DTC ads may confuse 
vulnerable people and seek drug promotion rather than educating consumers about important 
health issues (Royne & Myers, 2008; Tsai & Lancaster, 2012; Wolfe, 2002). Given these 
concerns about the advertising category, critics have voiced that DTCA possibly leads to an 
over-medicalized society that relates to an increase in the overall health care cost in society as a 
whole (Beltramini, 2010; Parker & Pettijohn, 2003). 
However, DTCA has already been allowed in the US. Despite the heated debate over the 
advertising category, considering both positive and negative aspects of DTCA, researchers need 
to examine how this advertising category may contribute to public health better. An alternative 
discourse of the debate would be on seeking knowledge on how to promote the public’s 
informed health decision through providing accurate and balanced health information and 
encouraging consumers to process them adequately. If essential health information can be 
effectively conveyed to and attended by consumers, this advertising category may successfully 
serve public health education goals. In this regard, research on how consumer characteristics 







Previous Research on DTCA 
A line of research has examined the content of DTCA. For instance, Sheehan (2007) 
found that in a majority of branded prescription drug websites, the presentation of risk 
information was significantly subordinate to that of promotional information. Hoek, Gendall, and 
Freetham (2012) found that medical information overload may result in reduced consumer 
comprehension. In this regard, Kaphingst et al., (2005) note that if consumers have a low level of 
health literacy, misunderstanding of the drug’s uses and risks could occur. These studies imply 
that the way of presenting health information in DTCA may affect consumers’ perception and 
decision making. 
 In terms of message appeals employed in DTCA, Macias, Pashupati and Lewis (2007) 
and Tsai and Lancaster (2012) found that most DTC ads employed both informational and 
emotional appeals to a similar degree. However, they note that if advertisers use emotional 
appeals more than informational appeals, it could make consumers’ attention stay away from 
detailed drug attribute information (Tsai & Lancaster, 2012). 
 Another body of studies addressed consumer attitudes toward DTCA. Vatjanapukka and 
Waryzak (2004) found that those who have been frequently exposed to DTC ads showed more 
favorable attitudes toward the DTCA category. Women reported more favorable attitudes toward 
DTCA (Robinson et al., 2004). In addition, senior Americans showed more favorable attitudes 
toward DTCA than younger Americans (Williams & Hensel, 1995). 
 Recently, in response to the FDA’s interest in consumer perception (FDA, 2009), 
research has examined various DTCA message strategies in terms of their effects on consumer 





affect consumers’ evaluations of the ads. Shim, Cappella, and Leman (2010) also found that 
presenting familiar health risks may improve consumer involvement with the ad. Ju and Park 
(2013) examined the effects of numerical information in DTCA on consumers’ evaluations of the 
ad and found that numerical drug information could enhance consumers’ perceived effectiveness 
and attitudes toward the ad.  
In sum, prior research could be categorized into four broad groups. First, one program of 
research has examined the content of DTCA in terms of the relative proportion of benefit and 
risk information. Second, message appeals have been a popular topic in the DTCA literature. 
Third, general consumer attitudes toward DTCA have been examined. Finally and more recently, 
research began to examine the effects of message strategies on consumers’ perception and 
behavior regarding health issues. 
However, despite this abundance of DTCA research, little research has explored how risk 
disclosure presentation formats have consequences for consumer response to the ad, and how 
individual differences in consumer characteristics influence such processes. Risk disclosure in 
DTCA is required by the fair balance requirement (21 CFR 202.1) and examining the impact of 
risk disclosure format represents an important research initiative. Nevertheless, since 2009 when 
the FDA issued draft guidance of risk communication in DTCA, rare research has provided 
empirical findings regarding various message execution factors outlined in the draft guidance, 
while considering various consumer-side factors. To better understand the impact of DTCA on 







The Fair Balance Requirement of DTCA 
 The FFD&C Act (21 U.S.C. 352) requires pharmaceutical marketers to present any word, 
statement, or other information in advertising prominently to render them to be read and 
understood by the ordinary individual under customary conditions of purchase and use. In 
particular, pharmaceutical manufacturers are obligated to provide important health risk 
information conspicuously in their promotional materials (21 CFR 202.1). The provision of 
important risk information in advertising is referred to as risk disclosure (or disclaimer) and its 
major purpose is to offer consumers an opportunity to consider potential risks of the product 
before purchase and use, and thereby help them make sound purchase decisions (Andrews, 
Netmeyer, & Burton, 2009; Stewart & Martin, 2004). 
 In this regard, the fair balance requirement of benefit and risk information in DTCA has 
received considerable research attention. A number of studies have examined whether 
pharmaceutical advertisers comply with the requirement through examining the content of 
DTCA (e.g., Huh & Cude, 2004; Kaphingst et al., 2004; Macias & Lewis, 2003; Macias et al., 
2007, 2010; Sheehan, 2007; Sumpradit et al., 2004). The FFD&C Act (21 U.S.C. 352) and 
FDA’s regulations (21 CFR 202.1) clearly state that DTCA must present information about the 
drug's effectiveness and risk in a fairly balanced manner in terms of content and format. In 
particular, in its 2009 draft guidance for industry on the risk information presentation in 
prescription drug promotion, the FDA provides specific guidelines for pharmaceutical 
advertisers regarding how they can develop the content and format of DTCA to comply with the 
FD&C Act. It is worth noting that the guidance provides a list of message execution factors that 





 Importantly, the FDA (2009) points out that it views consumers’ net impression about the 
drug as an important consideration when reviewing DTCA. This agency clearly indicates that its 
concern about consumer impression draws on well-developed social science theories (FDA, 
2009) and the concern is in alignment with the approach of other agencies such as the Federal 
Trade Commission’s (FTC, 1984) policy statement on deception (103 F.T.C. 110, 174). For 
instance, according to the FTC statement, advertising deception can be determined by examining 
the overall consumer impression created by a certain advertising practice, claim, or 
representation (103 F.T.C. 110, 174). In a similar vein, pharmaceutical industry members have 
also conducted research and pointed out that the net impression shaped by the ad as a whole is an 
important aspect to consider, independent of specific claims within the ad (PhRMA, 2009). 
 However, the majority of DTC ads tend to emphasize the benefits of the drug more 
prominently than risks (Lexchin & Mintzes, 2002; Macias et al., 2007; Sheehan, 2007; Roth, 
1996). A concern is whether the risk disclosure secures sufficient consumer attention to risk 
information (Kopp & Bang, 2000). If an ad fails to present the disclosure with sufficient 
prominence, the provision itself will not be effective for encouraging consumers to consider the 
potential health risks of the drug use (Davis, 2010; Davis & Meader, 2009; Hoek et al., 2011).  
In this regard, the FDA issues administrative letters (i.e., warning letters and untitled 
letters) directly to the advertiser and publicize on the FDA’s website when an advertiser violates 
the fair balance requirement. Among others, risk minimizing practices have been frequently cited 
as one type of violation in the letters (Huh & Becker, 2005; Sheehan, 2003, 2007). Minimizing 
drug risk is likely to result in consumers’ inappropriate prescription drug requests and uses. 





offer invaluable insight. 
 
Risk Disclosure in DTCA 
 Advertisers exert efforts to present their products and services in a favorable light in ads, 
and thereby make them stand out among their competitors in a positive way (Eisend, 2006; 
Kamins, Brand, Hoeke, & Moe, 1989). From the advertiser’s perspective, disclosing negative 
aspects of brands may be less welcome (Franke, Huhmann, & Mothersbaugh, 2004; Hoek et al., 
2011; Kavadas et al., 2007). In line with this, researchers have noted that pharmaceutical 
advertisers may be motivated to present serious health risks of the medicine inconspicuously, 
while seeking to emphasize the benefits of it (e.g., Kavadas et al., 2007; Roth, 1996; Royne & 
Myers, 2008; Morris & Millstein, 1984). As a matter of fact, research found that disclosing 
health risks of drugs in DTC ads may result in unfavorable consumer response to the drug. For 
instance, a higher ratio of risk information compared to the ratio of benefit information was more 
likely to decrease consumers’ behavioral intentions to use the promoted drug (Kavadas et al., 
2007; Royne & Myers, 2008). 
With regard to this, some consumer advertising categories have been required to present 
important risk information associated with the use of products and services in their promotional 
materials, a practice commonly named disclosures (or disclaimers) (Andrew et al., 2009). The 
purpose of advertising disclosure is to clarify or qualify potentially misleading or deceptive 
statements made within an ad (Hoy & Andrews, 2004). 
Disclosures are a regulatory action to promote consumers’ complete understanding about 





Martin, 2004). Advertising disclosure can take on various forms including product claims, risks 
of product usage, and information about reducing or avoiding risks (Stewart & Martin, 2004). In 
light of this, DTCA risk disclosure typically provides information about important health risks, 
side effects, and contraindications, associated with the use of prescription medicine.  
 Today, advertising disclosure became prevalent in the consumer information environment 
(Andrews et al., 2009). The majority of consumers are aware of that disclosures are required by 
law in certain product categories such health warnings in cigarette advertising (Eisend, 2006). In 
this context, consumers should be able to utilize such disclaimers to make informed purchase 
decisions (Foxman, Muehling, & Moore, 1988). Disclosures that are clearly and prominently 
displayed can be effective for reducing misbeliefs and shaping attitudes and intentions (Hoy & 
Stankey, 1993; Andrews et al., 2000; Wilkie, 1985). Furthermore, pharmaceutical advertisers can 
be also protected from potential undue accusations of misleading or deceptive advertising, 
assuming that the advertisers meet the risk disclosure requirements appropriately (Andrews et al., 
2000). 
In the DTCA context, pharmaceutical advertisers are obligated to provide important 
health risk information in DTC ads (21 CFR 202.1). However, to help prescription drug 
consumers make sound prescription decisions, researchers need to understand how information 
about health risks of the drug can be displayed more effectively. To do so, a consumer-oriented 
research approach will provide insight into the development of more effective DTCA risk 
communication. In addition, this approach also allows researchers to better understand the risk 
disclosure processing mechanism from the consumer perspective. In the following section, the 





disclosure prominence may help information processing. 
 
Consumer Information Processing and DTCA Disclosure Prominence 
Various advertising message strategies have been reported to result in varying consumer 
responses to the ad (e.g., Lee et al., 2011a, 2011b; Liebermann & Flint-Goor, 1996). Extending 
this view to DTCA risk disclosure processing, risk disclosure presentation strategies are likely to 
affect consumers’ responses to the disclosure (Davis, 2010; Davis & Meader, 2009; Hoek et al., 
2011; Kavadas et al., 2007; Ju & Park, 2013). For instance, various message factors such as the 
amount, emphasis, and specificity of messages will influence how risk disclosure is processed by 
consumers (Kavadas et al., 2007; Morris, Ruffner, & Klimberg, 1985). 
From a consumer information processing perspective, the success of risk disclosure 
provision accrues to the extent that consumers notice, process, and comprehend such information 
properly (Bettman & Kakkar, 1997; Bettmam, Payne, & Staelin, 1986; MacCarthy & 
Mothersbaugh, 2002; MacInnis & Jaworskin, 1989; MacInnis, Moorman, & Jaworski, 1991). In 
particular, to encourage consumers to pay sufficient attention to risk disclosure in advertising, 
disclosures need to be displayed clearly and conspicuously (Hoy & Andrew, 2004).  
This thought is reflected in the clear, conspicuous, and neutral (CCN) requirement added 
to the amended FFD&C Act by the Food and Drug Administration Amendments Act of 2007 
(DHHS, 2010). Although the amendment was targeted at DTC television or radio ads, the 
principle is applicable across different DTCA practices in that it aims to improve risk 
communication in DTCA in general. According to the CCN requirement, the major statement 





presented in a clear, conspicuous, and neutral manner (DHHS, 2010).  
The main purpose of the CCN requirement is to encourage DTC advertisers to present 
potential health risk information in a more prominent manner to be easily attended and processed 
by the consumer. In light of this, message strategies that promote consumers to easily pick out 
and make use of such information are an important prerequisite for proper processing of DTCA 
disclosures (Hoek et al., 2011). 
In the same token, the FDA’s (2009) draft guidance of risk communication provides a 
useful list of message execution factors that are expected to affect consumer processing of risk 
disclosure, including overall location of risk disclosure, its font size, contrast, white space, etc. 
No matter what execution devices are employed, if an ad fails to provide sufficient emphasis on 
risk disclosure comparable with benefit information, it is considered a lack of fair balance (21 
CFR 202.1(e)(7)(viii)).  
 Why does the prominence of DTCA risk disclosure matter? From an information 
processing perspective, disclosures are critical communication tools and remedies when 
consumers use potentially risky products or services (Andrews, 1998). Well-executed risk 
disclosure provision can reduce inappropriate impression about promoted drug brands (Sheehan, 
2007). Furthermore, disclosures can broaden consumers’ cognitive reference and thereby help 
them avoid unrealistic generalization of the product’s efficacy (Andrews et al., 2000; Andrews et 
al., 2009). 
 Andrews et al. (2009) summarize main cognitive functions of disclosures. Disclosures 
allow consumers to access important risk information that is central to their decision making, and 





disclosure can serve as a diagnostic reference point used for evaluating the ad claims. In the 
same vein, disclosures can broaden the cognitive frame, and as a result reduce inappropriate 
generalizations of the product’ efficacy. Based on this, disclosures may contribute to enhanced 
accessibility, diagnosticity, and comprehension of advertising information (Andrews et al., 
2000).  
Based on the literature, if disclosures are presented prominently in DTCA, consumer 
processing performance will increase for information on the potential health risks of the drug. 
Assuming that a major goal of DTCA disclosure is to educate consumers about important health 
risks of the drug, risk disclosure prominence should be a critical research agenda to promote 
consumers’ sound health decisions. 
 
Cognitive Fluency and Risk Disclosure Processing 
With regard to risk disclosure processing, consumers’ cognitive fluency represents an 
important consideration. Consumer information processing is affected by a wide range of factors 
and cognitive fluency has been known to play an important role (Bettman & Kakkar, 1977; 
Bettman et al., 1986; Moorman, Diehl, Brinberg, & Kidwell, 2004). During the 1970s and 1980s, 
a body of research attempted to examine the utility of information processing principles in 
examining risk disclosure effects (e.g., Dyer & Shimp, 1977; Jacoby & Small, 1975; Wilkie & 
Gardner, 1974). The studies suggested in common that effective disclosure programs need an 
understanding of consumer information processing mechanisms (Mazis & Staelin, 1982). In this 
regard, borrowing from information processing research will shed much light on understanding 





 Hierarchy-of-effects communication models provide a theoretical foundation of the 
current research. McGuire (1976) was one of frontiers who laid out the theoretical framework to 
understand consumer information processing sequences. According to his framework, consumers 
typically goes through a serious of sequences in acquiring, processing, and using information. 
More specifically, the sequences have at least five folds: exposure, attention, comprehension, 
retention/retrieval, and decision making (McGuire, 1976). Although these phases are not always 
clearly distinct from each other or do not always go through this order, the framework serves as a 
useful foundation for examining how consumer information processing operates and which 
cognitive factors should be examined (Mazis & Staelin, 1982). 
More importantly, the model suggests that there could be factors that enhance or impede 
communication effectiveness. In light of the current research, an important information 
processing phase may be attention. Attention measures serve as an important variable for the 
early stages of information processing (Krugman, Fox, Fletcher, Fischer, & Rojas, 1994). It has 
been well-documented that despite their limited cognitive capacity (Lynch & Srull, 1982; Mazis 
& Staelin, 1982), today’s consumers are exposed to a vast amount of marketplace information 
(Boush et al., 2009; Knowles & Linn, 2003). If advertisers fail to attract consumer attention to 
important product attribute information, communication effectiveness will be significantly 
decreased (Krugman et al., 1994).  
Once consumers paid sufficient attention to information, consumers should be able to 
retrieve the stored information, and more prominent information is more likely to be retrieved in 
a decision making situation (Alba & Hutchinson, 1987; Lynch & Srull, 1982). When consumers 





process referred to as encoding. Prominence of information has been regarded as a factor that 
enhances ease of encoding (Alba & Hutchinson, 1987; Lynch & Srull, 1982). That is, more 
prominent events in the information environment are more likely to enhance consumer encoding 
of information (Bettman et al, 1986). In this regard, Mazis and Staelin (1982) note that 
information presented in a confusing manner is more difficult to encode and retrieve (i.e., 
decode). This line of studies suggests to examine the effects of prominence on consumers’ 
attention and memory.    
 
The Influence of Cognitive Structure 
To better understand the risk disclosure processing phenomenon, one needs to look to 
consumer-side aspects as well as message-side factors. Mazis and Staelin (1982) note that 
attention and information retention/retrieval are affected by both internal and external factors. 
As noted, external factors may involve the characteristics of the message itself such as risk 
disclosure prominence. On the other hand, internal factors may include consumer capacity and 
motivation to process the information (Mazis & Staelin, 1982). In particular, cognitive structure 
such as persuasion knowledge has been suggested as an important consideration in information 
processing (Alba & Hutchinson, 1987; Friestad & Wright, 1994; Goodstein, 1993; Kardes et al., 
2004). In light of this, examining the interplay between internal and external factors may provide 
invaluable insight into our understanding of consumers’ risk disclosure coping strategies. 
Among others, the current research addresses DTCA regulatory knowledge to examine 
how consumers’ category-based processing (Goodstein, 1993) affects their response to the DTC 





expectations to their motivation to process and evaluate information stimuli (Sujan, 1985). This 
category knowledge structure is referred to as schemata (Goodstein, 1993). Advertising schemas 
are developed through repeated learning regarding a particular advertising category, and this can 
involve semantic and structural features (Friestad & Wright, 1994). Based on the literature, 
therefore, it is expected that consumers’ cognitive schemas regarding a particular regulatory 
context for ad design (i.e., DTCA regulatory knowledge) can be organized around product 
categories (Goodstein, 1993). In addition, individuals may have different levels of DTCA 
regulatory knowledge because they may have varying levels of experience with DTCA. 
Addressing the role of DTCA regulatory knowledge may shed light on how consumers cope with 
DTCA information using their regulatory schema regarding the DTCA category, which is an 
underexplored area. 
 
DTCA Regulatory Knowledge and Risk Disclosure Prominence 
The notion of information encoding (i.e., storing) and decoding (i.e., retrieving) 
proficiency is often associated with preexisting memory structure (Bettman et al., 1986; Mazis & 
Staelin, 1982). As noted, cognitive schemata involve how information is organized in a long-
term memory regarding a particular category. DTCA regulatory knowledge may represent one 
type of cognitive schemata regarding the DTCA category. This knowledge can include overall 
understanding of FDA’s overall control over DTCA, particularly its content and design, and 
developmental and approval process. In addition, textual schemata relate the extent to which 
consumers are familiar with a particular way of information presentation in a particular 





to learn about how DTCA tends to present information about the medicine (i.e., headline, uses 
and efficacy information, and risk disclosure) and how such information is regulated by law, the 
overall heuristic based on type regulatory and textual schemata regarding DTCA serves as 
cognitive processing facilitators. That is, information organization that is compatible with 
consuimers’ pre-existing schemata would be more easily recognized and therefore effective 
(Sheehan, 2007). Although Sheehan (2007) notes that textual schemata would facilitate 
consumer information processing from DTCA, given the unique regulatory context of DTCA for 
ad design, examining the interactive influence of textual and regulatory schemata could provide 
richer insight into our understanding of risk disclosure effects.  
In this regard, consumers are more likely to view that important information is 
highlighted using various message execution devices such as color, font, size, or location. The 
risk disclosure prominence effects could be a result of consumers’ textual schemata. On the other 
hand, those who have high DTCA regulatory knowledge may recognize the advertising category 
must present important risk information and are more likely to look to risk disclosure to make 
sound health decisions regardless of textual devices. Based on this, DTCA regulatory knowledge 
could serve as heuristic inference cues and will signal consumers’ locating of risk disclosure 
information in DTC ads. When DTCA regulatory knowledge is high, consumers’ diagnocity of 
risk information in DTC ads will be high, and such enhanced diagnocity is more likely to 
improve cognitive performance regarding locating and memorizing information (Kardes et al., 
2004). 
On the other hand, DTCA regulatory knowledge, as consumer marketplace persuasion 





varying levels of DTCA regulatory knowledge. Among those with high DTCA regulatory 
knowledge, their superior regulatory and textual schemata regarding risk disclosure presentation 
will lead to improved search selectivity and memory of risk information, whereas among those 
with low DTCA regulatory knowledge, varying levels of risk disclosure prominence plays a 
more important role as peripheral signals or cues (Petty & Cacioppo, 1986) and consumers are 
more likely to activate their general textual schemata dominantly than regulatory schemata. That 
is, more prominent risk disclosure is more likely to provoke enhanced search selectivity and 
thereby improved memory of information. Put differently, among less knowledgeable 
individuals, a heuristic cognitive path for textual schemata will prevail, such that more prominent 
disclosure will be easily detected and utilized, whereas less prominent disclosure will be less 
attended and memorized. Based on the foregoing review of literature, examining the role of 
DTCA regulatory knowledge will illuminate how consumers’ knowledge about the DTCA’s 
regulatory context may improve their DTCA health risk information coping strategies. 
 
The Framework of Dissertation 
Conceptualization of Risk Disclosure Prominence in the Literature 
 It has long been documented that a wide range of advertising message factors affect 
consumer perception and behavior (e.g., Jackson, 1992; Liebermann & Flint-Goor, 1996; 
O’Keefe, 2002, 2003; Taylor, 1999). A number of studies have examined whether vivid 
messages are more effective than non-vivid messages (e.g., Collins, Taylor, Wood, & 
Thompson, 1988; Frey & Eagly, 1993; Taylor & Thompson, 1982). The literature on message 





motivation and ability to process information, including message specificity (Morris & Millstein, 
1984), the amount of information (Tucker & Smith, 1987), the emphasis of risk information 
(Morris, Ruffner, and Klimberg, 1985), and the completeness of risk information (Davis, 2000). 
Andrews (1998) notes that these “message factors can play a pivotal role in the processing of 
disclosure information by consumers” (p. 1). Based on the literature, varying levels of risk 
disclosure prominence can lead to different communication effects.  
There could be various approaches to conceptualize message prominence. For instance, 
the location of the message in an ad may affect consumer perception about the ad (Crowley & 
Hoyer, 1994; Haugtvedt & Wegener, 1994). Pieters, Rosenbergen, and Hartog’s (1996) eye-
tracking study found that subjects processed ad headline first, followed by body copy visual 
among others. This finding implies that information in the top portion of the ad may be more 
likely to attract viewers' attention than other information elements in the ad (Royne & Myers, 
2008). However, Main, Argo, and Buhman (2004) examined print DTC ads and found that risk 
information was typically presented at the bottom of the ads. In this case, because the relegated 
risk disclosure is less noticeable, consumer decision making will be based exclusively on 
information about drug efficacy that is typically presented in a more noticeable portion of ads. 
In the context of DTCA risk disclosure, if consumers pay attention exclusively to the 
medicine’s efficacy, they are more likely to dismiss risk information that is central to informed 
health decisions. Considering that consumers typically do not pay much attention to risk 







The FDA’s Conceptualization of Risk Disclosure Prominence in DTCA 
 It is worth noting how the FDA conceptualizes risk disclosure prominence and guides 
pharmaceutical advertisers regarding the development of DTCA risk communication. The FDA 
(2009) conceptualizes that disclosure prominence could consist of various message execution 
variables rather than a particular message implementing factor. The agency pays attention to 
consumers’ net impression as a whole (FDA, 2009). For instance, if a DTC ad presents risk 
disclosure in smaller, non-bolded font without sufficient surrounding white space, while benefit 
information is presented in larger bolded font with abundant surrounding white space, this 
practice may be regarded as risk-minimizing or potentially misleading (FDA, 2009). 
 This conceptualization is well represented in the FDA’s administrative letters (i.e., 
warning or untitled letters) explaining pharmaceutical advertisers’ violations of the fair balance 
requirement. These letters signal to the advertisers their violative promotional practices and 
advise them to release corrective advertising if needed (FDA, 2009). During the period of 1997-
2001 the FDA issued between 15 and 25 letters per year, citing DTC promotional materials (US 
Government Accountability Office; GAO, 2008). From 1997 to 2002, the FDA issued 99 
administrative letters (Sheehan, 2003). In addition, from 2002 to 2005, the agency issued 
between 8 and 11 regulatory letters per year that cited DTC promotional materials (GAO, 2008). 
Although the GAO points out that the overall number of letters per year has continued to decline, 
given that the 2002 policy change lengthened the agency’s process for issuing letters, it is hard to 
judge whether pharmaceutical advertisers’ misleading or risk-minimizing DTCA practices have 
continuously decreased. Rather, the GAO (2006, 2008) recommends that the FDA improves their 





prioritizing all materials that the agency receives for review. 
Among various problematic DTCA practices, a number of letters state that the 
promotional materials for prescription drugs employed message techniques that are likely to 
minimize consumers’ risk perception about the medicine through a wide range of message 
presentation formats (Sheehan, 2003). More importantly, even when the ads presented required 
risk information, they appeared to fail to provide sufficient prominence of risk disclosure 
comparable with that of benefit information (Sheehan, 2003). This is undesirable given that 
imbalanced emphasis on benefit information is likely to relate to unrealistic perception about the 
medicine’s efficacy, while leading consumers to disregard potential health risks of the drug (An 
& Muturi, 2011). To address this public health concern, the current research builds on the FDA’s 
conceptualization of risk disclosure prominence and operationalizes disclosure prominence as a 
combination of various message factors that are selected from the FDA’s (2009) draft guidance 
of DTCA risk communication.  
To be more specific, the FDA (2009) lays out major risk minimizing message techniques 
in their draft guidance, titled “Presenting Risk Information in Prescription Drug and Medical 
Device Promotion.” This guidance states that promotional materials are misleading if they fail to 
present information about risks associated with a drug with a prominence reasonably comparable 
to the presentation of information related to the effectiveness of the drug.  
In particular, the FDA takes into account “all implementing factors such as typography, 
layout, contrast, headlines, paragraphing, white space, and any other techniques apt to achieve 
emphasis" (21 CFR 202.1(e)(7)(viii)). To encourage consumers to make informed prescription 





information about the drug’s efficacy or uses. Further, the information should be properly 
recalled or recognized in their decision making situations. Depending on how advertisers use the 
above message techniques to present risk disclosure, prominence can be differently 
operationalized. In this research, two levels of disclosure prominence is operationalized to 
represent high and low prominence, using the techniques outlined by the FDA (2009). 
 In sum, the Code of Federal Regulation (21 CFR 202.1) and the FDA’s draft guidance for 
prescription drug promotion (FDA, 2009) clearly document how risk information as well as 
benefit information can be developed to be noticeable so that consumers are able to pay 
sufficient attention to both information with similar ease. Based on the foregoing discussion, in 
the following section the theoretical background and operationalization of DTCA risk disclosure 
prominence are addressed. 
 
The Study 
Risk Disclosure Prominence as a Message Factor (Main Effects) 
  To secure intended risk disclosure effectiveness, DTCA designers should consider 
persuasion sequences including exposure, processing, and action (Bettman et al., 1986; 
Wogalter, Conzola, & Smith-Jackson, 2002). In particular, as to advertising execution factors, 
DTCA researchers have paid attention to the exposure stage because attracting consumers’ 
attention to risk disclosure is the first step for effective advertising campaigns (Hoek et al., 
2011).  
 A couple of theoretical perspectives on consumer information processing provide 





selective attention research suggests that human information processing capacity has limitations 
and therefore consumers tend to select and focus more on particular portion of the message at a 
time (e.g., Bettman et al., 1986; Lavie, 2001; Mayer & Moreno, 2003; Miller, 1994; Paas, Renkl, 
& Sweller, 2004). 
Regarding DTCA, these cognitive limitations are more likely to be found. Compared with 
health professionals, novice consumers will have limited medical knowledge. For this reason, 
negative medical information presented less prominently is more likely to result in information 
avoidance. In general, prescription drug advertising presents more difficult medical information 
compared with over-the-counter (OTC) drugs (Andrews, 1998). Based on this, less 
knowledgeable consumers are more likely to selectively attend particular information in the DTC 
ad to reduce cognitive overload (Alba & Hutchinson, 1987). 
This implies that information that causes cognitive overload in DTCA may result in 
biased net impression about the medicine (Hoek et al., 2011). To ordinary consumers, less 
prominent risk disclosure is likely to cause cognitive fatigue because it requires consumers to 
exert more efforts to find and focus on the less legible messages (Davis, 2010). More prominent 
disclosure could encourage less knowledgeable consumers to closely scrutinize DTCA risk 
information (Wilkie, 1986). 
 Depending on risk disclosure prominence, ease of processing may vary. This study 
examines perceived attention as a proxy measure of objective attention. As cognitive fluency is 
likely to be affected by prominence (e.g., Hyönä & Lorch, 2004; Lorch, Lorch, & Inman, 1993; 
Loman & Mayer, 1983; Spyridakis & Standal, 1987), perceived attention to risk disclosure will 





and recognition performance. In this regard, this research addresses risk disclosure prominence 
as an important message factor regarding consumers’ informed prescription decision making. 
Operationalization of Risk Disclosure Prominence 
A couple of typographical devices are utilized to operaionalize risk disclosure 
prominence of DTCA. Those factors include text color, title, font size, bold texts, box outline, 
and location based on the FDA’s (2009) risk communication draft guidance. To be more specific, 
to manipulate the risk disclosure prominence, this research employs a couple of attention 
signaling cues. Signaling can be defined as the use of typographical devices designed to 
highlight aspects of a text’s structure or content without altering the information in the ad (Lorch 
et al., 1993).  
Among others, most widely employed signaling devices may include headlines or 
subheads (Hyönä & Lorch, 2004). The FDA (2009) requires that pharmaceutical promotional 
materials use appropriate typographical signals consistently across benefit and risk information 
to foster accurate and non-misleading impressions about the drug. Furthermore, the literature 
suggests that product warnings need to employ vivid colors and noticeable font sizes, and use 
any symbols to summarize and reinforce key warning details, which would help consumers 
easily locate risk information (Bettman et al., 1986). 
 In a similar vein, Argo and Main (2004) conducted a meta-analysis and found that vivid 
color such as red enhances consumer attention to risk information. In addition, physical location 
of risk information may affect message prominence (Hoek et al., 2011). For instance, risk 
information close to benefit information was found to be more noticeable than risk information 





found to be superior to texts without outlines in leading attention to information and retaining 
memory for short periods (Bettman et al., 1986; Hoek et al., 2011; Wogalter et al., 2002; 
Wogalter & Shaver, 2001). 
In this dissertation, based on the FDA’s (2009) draft guidance, the previous literature on 
risk disclosure presentation, and the preliminary analysis of hundreds of DTC ads, the attention-
enhancing factors were selected, including the use of cueing signals (i.e., bullet points, bold 
texts, capitalized first words), use of color (i.e., red), boxed frame lines, larger font sizes, and 
position of texts (i.e., close to use and benefit information vs. bottom of  the ad). In contrast, the 
less prominence condition is manipulated as disclosures using no bullet points, no bold texts, no 
capitalization of first words, no red color, no box lines, smaller font sizes, and relegation toward 
the bottom of the ad page.  
 
Research Hypotheses 
Perceived Attention to Risk Disclosure 
 Researchers consider attention an important cognitive process that affects consumers’ 
decision making outcomes (Lynch & Srull, 1982). However, it is worthy to note selective aspects 
of attention. Regarding risk disclosure, physically salient information in the environment is more 
likely to capture a disproportionate amount of attention (Taylor & Fiske, 1978). Given this, 
consumers’ attention to DTCA risk disclosure may play a role in leading them to discuss the 
risks of taking the drug with their doctors (Menon, Deshpande, Perri III, & Zinkhan, 2003). 
More specifically, in the context of risk communication in advertising, attention has been 





1994). Although risk disclosure has become a common phenomenon in the contemporary 
information environment (Mazis, Morris, & Swasy, 1991), surprisingly few empirical studies 
have assessed its effectiveness in the DTCA context. Advertising research has reported that mere 
advertising exposure itself is not always effective for promoting intended consumer response to 
the ad (Goodrich, 2011). Consumer attention to ad information needs to be secured and different 
ad stimuli (e.g., ad type, ad location, and page type) can affect varying attention levels 
(Goodrich, 2011).  
There could be various ways to conceptualize and measure attention (i.e., behavior 
observation, psychophysiology, and self-reports), and each approach has their own 
methodological pros and cons (Reeves & Thorson, 1986; Thorson, Chi, & Leavitt, 1992). One of 
the commonly employed measurement approaches to attention is introspective self-observation 
(i.e., self-reported) (Chaffee & Schleuder, 1986). In particular, given that more often than not 
resources and instruments for objective measures of attention are not available to researchers, the 
simplest and available way to assess attention is self-reports (Reeves & Thorson, 1986; Thorson 
et al., 1992), referred to as perceived attention or self-reported weight of watching. In this regard, 
despite criticism that perceived attention has limitations for measuring actual attention, as an 
alternative proxy measure of attention, researchers have often employed the subjective measure 
(e.g., Thorson et al., 1992). 
The use of self-reported perceived attention can be justified from the cognitive inference 
literature. Although consumers’ self-beliefs about a particular phenomenon is seldom complete 
or errorless, consumer research on meta-knowledge has found that their subjective or perceived 





This has been often labeled as cognitive heuristics (Kardes et al., 2004). Therefore, although 
perceived attention measure cannot represent an ideal approach to assessing objective attention, 
the utility of it has been acknowledged (e.g., Reeves & Thorson, 1986; Chaffee & Schleuder, 
1986; Thorson et al., 1992). In particular, Chaffee and Schleuder (1986) note that the subjective 
attention measures are notable for their utility and general validity than for their reliability and 
precision. Given the literature, with rigorous theoretical underpinning and careful caution in 
interpreting the research findings, perceived attention measure, as a proxy measurement 
approach, can provide consumer researchers with usability to better understand the phenomenon 
of consumer attention to advertising. Further, if the researcher employ other theoretically 
relevant construct measures simultaneously, the construct (e.g., convergence validity) validity or 
criterion validity (e.g., predictive validity) can be assessed. Based on the consideration of these 
various methodological issues and limitations, the current research in that regard employs a self-
reported perceived attention measure (see the method section for more information). 
Taken together, for consumers to make sound prescription decisions, risk disclosure 
information should be attended so that they can utilize the information reasonably. Prominent 
risk disclosure in a DTC ad may prime important product attributes such as potential health risks, 
adverse reactions, and contraindications, and thereby make risk information more accessible 
from memory (Menon et al., 2003a). Varying levels of risk disclosure prominence are predicted 
to result in disproportional levels of attention. Higher prominence disclosure are more likely to 
lead to higher consumer attention to risk disclosure than lower prominence disclosure. Based on 
the review of literature on prominence and attention, the following hypothesis can be raised: 







Recall and Recognition of Risk Disclosure 
 Advertising exposure has an impact on consumers’ recall and recognition (Okechuku, 
1992; Pechmann & Stewart, 1990; Rosbergen, Pieters, & Wedel, 1997; Shapiro & Krishnan, 
2001). Although these two cognitive measures have been widely employed in the advertising 
literature, the measures of recall are often criticized because they may underestimate advertising 
effectiveness under low levels of cognitive elaboration conditions (Petty et al., 1983). In general, 
a recall test involves a situation where a subject must independently retrieve previously acquired 
information (e.g., subjects are asked to list all product attributes learned from an ad). On the 
other hand, in a recognition test, subjects are given a list of choices and must indicate which one 
was previously presented in the ad. However, Due to the different cognitive task difficulties 
between the two methodological approaches, in general recall score is reported as lower than 
recognition score (Lynch & Srull, 1982), implying that statistical variations in recall tests might 
be minimal. Nevertheless, the use of recall measure for advertising effectiveness can represent 
the levels of cognitive elaboration devoted to processing information, indicating active cognitive 
processing (Lord & Burnkrant, 1993).  
Given the advantages and disadvantages of the two memory measures, cognitive 
psychology suggests that one of the most simple and parsimonious approach to measure 
information retrievability takes a two-stage process, where subjects must independently retrieve 
information (i.e., unaided recall) and then perform some recognition check on whether the item 





recognition theory (Lynch & Srull, 1982). Researchers are advised to employ recognition 
measures to complement the limitations of the recall measure in advertising message research 
(Okechuku, 1992). In this regard, the current research adopts the generation-recognition 
approach to assess consumer risk information retrievability. 
 There are robust findings that information organization is important for memory 
performance (Lynch & Srull, 1982). Some organizational formats may facilitate the retrieval 
fluency and, therefore, information presentation formats are important for memory-based 
judgments (Lynch & Srull, 1982). Greater attention to information is more likely to lead to 
greater focus on product’s facts and objective attributes (Alba & Hutchinson, 1987; Lynch & 
Srull, 1982; Okechuku, 1992; Park & Lessig, 1981) and such increased focus on information 
may lead consumers to memorize more details of the information. 
 Therefore, when the consumer takes a memory test, more prominent risk disclosure will 
lead to higher recall and recognition scores (Lynch & Srull, 1982). In the context of DTCA, 
examining recall and recognition of the drug’s health risks may provide important educational 
implications (e.g., Davis, 2010). Based on the literature, the following research hypotheses can 
be raised: 
H2: Higher risk disclosure prominence will lead to greater recall of health risk 
information. 
 









DTCA Regulatory Knowledge as a Consumer Factor (Main Effects) 
Another important factor that may affect DTCA risk disclosure processing in the current 
research is consumers' individual differences in DTCA regulatory knowledge. Depending on 
individuals' unique cognitive schema, their coping strategies of health information in DTCA will 
vary. Consumer behavior models have described knowledge as an individual difference variable 
affecting all phases of the decision process, especially information search (Beatty & Smith, 
1987; Brucks, 1985; Moorman, Diehl, Brinberg, & Kidwell, 2004). A number of researchers 
have examined the impact of knowledge on decision making (e.g., Alba & Hutchinson, 2000; 
Ellen, 1994; House et al., 2004; Park, Mothersbaugh, & Feick, 1994). In the same token, the 
PKM literature suggests that marketplace knowledge can affect consumer information processing 
of marketing messages (Friestad & Wright, 1994). From the PKM perspective (Friestad & 
Wright, 1994), DTCA regulatory knowledge can be viewed as one type of consumer marketplace 
beliefs in the DTCA context. Knowledge about a particular advertising category is expected to 
exert considerable influence on consumers’ information coping strategies (Boush et al., 2009; 
Obermiller & Spangenberg, 1998) and therefore DTCA regulatory knowledge may affect DTCA 
information coping strategies.   
As noted, in contemporary marketplace, consumers face a huge amount of persuasive 
messages and might have been socialized to develop certain beliefs or cognitive structure 
regarding such influence attempts (Boush et al., 2009; Darke & Ritchie, 2007). In order to 
protect their own interests, consumers employ such beliefs or cognitive structure in their 
information processing, referred to as epistemic doubt, and act as reasonable consumers in the 





consumers’ use of DTCA risk disclosure may be affected by such cognitive structure.  
Research on consumers’ knowledge of a product category has a long history in consumer 
research due to its effects on consumers’ decision making process (Engel, Blackwell, & Miniard, 
1990). Since Brucks (1985) described three categories of consumer knowledge including 
subjective knowledge that is what the consumer thinks he or she knows, objective knowledge 
that is measured by some type of test, and prior experience with the product category, many 
scholars have examined this construct (e.g., Alba & Hutchinson, 1987; Flynn & Goldsmith, 
1999). In addition, Peter, Olson, Grunert (1999) described that consumers have four levels of 
product knowledge, including product class, product form, brands, and models.  
However, given all this research attention, it is surprising that little research has 
addressed the conceptualization and measurement of it in the context of DTCA. In particular, 
despite attention on product category knowledge or issue knowledge, consumers’ cognitive 
structure regarding a particular advertising category’s regulatory context has been largely 
ignored in the DTCA literature. To better understand the impact of DTCA on consumers, 
researchers should examine not only its message aspects, but relevant consumer aspects such as 
individual differences in DTCA regulatory knowledge structure (Sheehan, 2007). 
As part of a broader set of marketplace beliefs, the current research referred DTCA 
regulatory knowledge to as “a set of cognitive structures about the FDA’s general control over 
DTCA, the FDA’s involvement with DTCA content and design, the ad category’s developmental 
and approval process, and the FDA’s involvement with DTCA research.” Despite a possibility to 
conceptualize DTCA regulatory knowledge in different ways, given a dearth of prior research on 






To develop a practical and valid measurement scale, this research adopts the measure 
items of DTCA regulatory knowledge from the FDA’s (2014) current page for consumer health 
education (i.e., For Consumers & Patients). This could have a couple of practical implications. 
First, the items represent actual consumers’ curiosity about the DTCA category. Low knowledge 
score could represent low levels of regulatory understanding for DTCA, whereas high 
knowledge score could represent reasonable understanding of the advertising category’s 
regulatory context. Second, the answer to each item reflects the FDA’s current thoughts and 
regulations about the DTCA category. Therefore, employing those items will provide practical 
insight into consumer education by the FDA and DTCA marketers. 
In general, knowledge about an advertising category enables consumers “to recognize, 
analyze, interpret, evaluate, and remember persuasion attempts and select and execute coping 
tactics believed to be effective and appropriate” (Friestad & Wright, 1994, p. 3). Given this 
presumed role of knowledge, consumers’ DTCA regulatory knowledge may serve as cognitive 
reference points for DTCA risk disclosure coping strategies. Consumers may be more or less 
motivated and/or able to process disclosures in DTCA, depending on varying levels of DTCA 
regulatory knowledge, because risk disclosure is part of regulatory requirement by the FDA. 
Research supports this theoretical prediction. In general, consumer responses to the ad are 
affected by individual differences in consumers’ motivation and ability to process information 
(Kavadas et al., 2007; Petty, Cacioppo, & Schumann, 1983). Research on systematic-heuristic 
inference (Chaiken & Eagly, 1989) and elaborated likelihood model (ELM) (Petty & Cacioppo, 





less affected by peripheral message factors such as information source (Petty et al., 1983) or 
presentation formats (Artz & Tybout, 1999), whereas less capable and motivated individuals are 
more affected by such factors. 
In addition, through the notion of consumer expertise, Alba and Hutchinson (1987) argue 
that higher consumer expertise tends to improve cognitive task performance regarding 
complicated information processing that requires cognitive resources. More knowledgeable 
consumers’ ability to process and utilize relevant information in decision making may be 
superior to that of less knowledgeable ones (Alba & Hutchinson, 1987). The preceding review of 
literature suggests the following research hypotheses: 
H4: Higher DTCA regulatory knowledge will lead to greater perceived attention to 
risk disclosure. 
 
H5: Higher DTCA regulatory knowledge will lead to greater recall of health risk 
information. 
 
H6: Higher DTCA regulatory knowledge will lead to greater recognition of health 
risk information. 
 
DTCA Regulatory Knowledge as a Consumer Factor (Moderating Effects) 
 Further, DTCA regulatory knowledge is expected to moderate the risk disclosure 
prominence effects. As has been discussed, individuals tend to select a more efficient cognitive 
path to reduce cognitive overload (Bettman & Zins, 1979; Wright, 1975). Given this theoretical 
premise, a concern is raised when DTCA presents disclosures in less prominent or less accessible 
formats. In general, DTCA provides medical information that requires more cognitive efforts 
(Macias et al., 2007; Royne & Myers, 2008). For instance, Sheehan (2006) examined the 





found that DTCA ads are among the most difficult ads. In particular, processing information that 
discusses the drug’s risks and contraindications is considered one of the most challenging 
cognitive tasks to novice consumers (Sheehan, 2006). Considering this nature of DTCA risk 
disclosure, more prominent risk disclosure provision will help low DTCA regulatory knowledge 
consumers locate and utilize risk information more fluently, because such message format is 
expected to reduce cognitive efforts required to process hard-to-read risk information whereby it 
improves information search selectivity. In contrast, higher DTCA regulatory knowledge may 
relate to higher cognitive capacity to search and utilize DTCA risk information, and therefore 
higher DTCA regulatory knowledge consumers may better perform cognitive tasks regardless of 
varying levels of risk disclosure prominence, indicating minimal prominence effects for higher 
DTCA regulatory knowledge consumers. 
 Further supports for the moderating influence of DTCA regulatory knowledge on the risk 
disclosure prominence effects can be found from the self-consistency hypothesis (Moorman et 
al., 2004). In general, when consumers perceive themselves as knowledgeable about a particular 
category, they are more likely to locate themselves proximate to information associated with that 
knowledge (Moorman et al., 2004). Extending this, consumers who are more knowledgeable 
about the FDA’s regulatory role for DTCA are more likely to be motivated and/or able to process 
risk disclosure required by regulation, because those with high DTCA regulatory knowledge will 
be more proficient with locating and utilizing risk disclosure in DTCA, referred to as high search 
selectivity (Moornan et al., 2004). Put simply, higher DTCA regulatory knowledge is more likely 
to be associated with higher search selectivity for risk disclosure in DTCA. This enhanced 





disclosures easily and therefore they will be less sensitive to risk disclosure prominence.  
In contrast, as to low DTCA regulatory knowledge consumers, their limited cognitive 
resources will result in more reliance on risk disclosure prominence to reduce their cognitive 
burden required for locating and processing risk disclosure to improve cognitive efficiency. 
When risk disclosure is presented more prominently, those with low DTCA regulatory 
knowledge will be more capable of attending and memorizing risk information, whereas when 
risk disclosure is presented less prominently, they will be less capable of locating and 
memorizing risk information. 
 Taken together, DTCA regulatory knowledge may moderate the risk disclosure 
prominence effects on consumer response to the ad. Those with low DTCA regulatory 
knowledge may rely more on disclosure prominence, such that more prominent disclosures are 
more likely to attract low knowledge consumers’ attention to risk disclosure, and thereby lead to 
enhanced memory of health risk information, including recall and recognition. In contrast, 
among high DTCA regulatory knowledge consumers, the prominence effects will be diluted, 
because highly knowledgeable consumers’ search selectivity and memory performance will be 
consistently high across varying levels of prominence. Therefore, the following hypothesis can 
be raised: 
H7: DTCA regulatory knowledge will moderate the risk disclosure prominence 
effects on: (a) perceived attention to risk disclosure; (b) recall; and (c) 
recognition of health risk information, such that low DTCA regulatory 
knowledge consumers will show greater prominence effects, whereas high 







The Mediating Role of Perceived Attention (Mediating Effects) 
 The foregoing sections address that certain formats and methods for presenting 
information can affect consumers’ perceived ease with information processing. For this reason, 
Bettman, Payne, and Stalein (1986) suggest that advertisers need to present product information 
in a way to reduce consumers’ cognitive effort/time required to locate and retrieve information. 
As a proxy measure of objective attention, perceived attention represents one type of indicator 
for cognitive fluency and examining this construct may provide insight into through what 
mechanism the effects of DTCA regulatory knowledge, risk disclosure prominence, and their 
interplay on consumer information retrievability operates. 
 In general, higher attention is expected to lead to greater memory of information 
(Goodrich, 2011). This is because more intensively attended and encoded information is more 
likely to be retrieved from memory (Pieters, Warlop, & Wedel, 2002). In this regard, some 
researchers view that enhanced information readability in terms of design can improve memory 
performance of the ad and brand (Moore, Stammerjohan, & Coulter, 2005). Therefore, attention 
to elements in advertising has been suggested as an important mediator of subsequent advertising 
effectiveness outcomes, including recall, attitudes, and purchase intentions (Mackenzie, 1986) 
and knowledge obtained from the ad (Chaffee & Schleuder, 1986).  
Extending this perspective to the context of DTCA regulatory knowledge, enhanced 
perceived attention resulting from higher DTCA regulatory knowledge and prominent risk 
disclosure may also strengthen subsequent memory performance of risk information, and further 
the interactive effects between DTCA regulatory knowledge and risk disclosure prominence will 





DTCA regulatory knowledge on the prominence effects, it is speculated that the mediating role 
of perceived attention will be substantial for the prominence effects among low DTCA 
regulatory knowledge consumers, whereas the mediating effects of perceived attention for the 
prominence effects will be diluted among high DTCA regulatory knowledge consumers, 
indicating a moderated-mediation relationship.   
Based on the foregoing discussion, perceived attention may mediate the effects of DTCA 
regulatory knowledge, risk disclosure prominence, and their interactive effects on consumers’ 
memory performance such as recall and recognition (Bettman et al., 1986; Sheehan, 2007). 
Therefore, the following hypotheses can be raised: 
H8: Perceived attention to risk disclosure will positively mediate the effects of risk 
disclosure prominence on consumer (a) recall and (b) recognition of health risk 
information. 
 
H9: Perceived attention to risk disclosure will positively mediate the effects of 
DTCA regulatory knowledge on consumer (a) recall and (b) recognition of 
health risk information. 
 
H10: Perceived attention to risk disclosure will positively mediate the interactive 
effects of risk disclosure prominence and DTCA regulatory knowledge on 
consumer (a) recall and (b) recognition of health risk information. 
 
The research hypotheses of the current research are summarized in Table 1. In addition, 






Table 1. Summary of Research Hypotheses 
Risk Disclosure Prominence Main Effects: 
 
H1: Higher risk disclosure prominence will lead to greater perceived attention to risk 
disclosure. 
 
H2: Higher risk disclosure prominence will lead to greater recall of health risk 
information. 
 
H3: Higher risk disclosure prominence will lead to greater recognition of health risk 
information. 
DTCA Regulatory Knowledge Main Effects: 
 
H4: Higher DTCA regulatory knowledge will lead to greater perceived attention to risk 
disclosure. 
 
H5: Higher DTCA regulatory knowledge will lead to greater recall of health risk 
information. 
 
H6: Higher DTCA regulatory knowledge will lead to greater recognition of health risk 
information. 
Moderating Effects of DTCA Regulatory Knowledge: 
 
H7: DTCA regulatory knowledge will negatively moderate the risk disclosure 
prominence effects on consumer response to the ad; such that low DTCA 
regulatory knowledge consumers will report higher (a) perceived attention to risk 
disclosure, (b) recall, and (c) recognition for high prominence risk disclosure than 
for low prominence risk disclosure, whereas high DTCA regulatory knowledge 
consumers will show minimal prominence effects. 
Mediating Effects of Perceived Attention: 
 
H8: Perceived attention to risk disclosure will positively mediate the effects of risk 
disclosure prominence on consumer (a) recall and (b) recognition of health risk 
information. 
 
H9: Perceived attention to risk disclosure will positively mediate the effects of DTCA 
regulatory knowledge on consumer (a) recall and (b) recognition of health risk 
information. 
 
H10: Perceived attention to risk disclosure will positively mediate the interactive 
effects of risk disclosure prominence and DTCA regulatory knowledge on 














Figure 1. The Conceptual Framework of Dissertation 
Prominence & DTCA Regulatory Knowledge Main Effects 
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CHAPTER 3: METHOD 
Procedure and Sample 
 Prior to the data collection, pretests were undertaken to ensure subjects' understanding 
and readability of the research instrument questions. In addition, the subjects in pretests served as 
the function of manipulation check groups (Perdue & Summers, 1986; Wetzel, 1977) to examine 
whether risk prominence was operationalized in a proper way. The test ads were reviewed by one 
advertising professor and three other communication professors. Based on their 
recommendations, the ad manipulations were revised several times to secure intended 
operationalization of ad stimuli. 
Then, confusing wording and unclear instructions were revised until the questionnaire is 
became clear and easily understood. The main experiment manipulated the prominence of risk 
disclosure by employing a set of message execution factors according to the FDA’s (2009) risk 
communication guidance. To ensure less-biased research findings, random sample assignment 
and statistical control of potential covariates were utilized according to the suggested 
experimental research approach (Goodwin, 2008; Shadish, Cook, & Campbell, 2002). Further, 
this approach has been also suggested in the health communication literature (e.g., An, 2007, 
Park, Ju, & Kim, 2013; Ju & Park, 2013). Two different test ads were created for a fictitious 
antidepressant brand (i.e., Luminexell) because mental depression is among major undertreated 
social diseases (FDA, 2014) and a fictitious brand can exclude alternative explanations in 
interpreting the findings (Shadish et al., 2002) (see the manipulation development section for 
more information). 





set of factors recommended the use of online consumer panel to conduct this research. First, it 
was an efficient way to reach relatively representative US adults. Second, the Internet access has 
been grown rapidly and the generation gap has been continuously narrowed. Third, to enhance 
the validity of the research, some of the questions were randomized to counterbalance any 
potential order effects. In particular, regarding random sample assignment, the faster and easier 
data collection allowed the researcher to better conduct research. Fourth, the Qualtrics consumer 
panel software provides promising response validation check features, including attention filters 
and average time duration screen out. There are many factors that may lead to respondent 
fatigue. One way to reduce the number of “straight-liners” and “speeders” is to insert attention 
filters into the survey. These questions verify respondents are reading the questions carefully and 
are following instructions. The most common type of attention filters is asking respondents to 
answer to “This is an attention filter. Please select “Strongly Disagree” for this statement.” If the 
respondent did not follow the instruction, the response was excluded from the results.  
In the same manner, to control the minimum time to submit the questionnaire, the 
researcher can enforce 1/3 of the average survey duration found during the pilot test phase. If 
there are respondents who attempt to take the survey in less than 1/3 the average time, the 
responses were removed from the results. Furthermore, to ensure the measurement validity of 
recall and recognition of risk disclosure, respondents were not allowed to go back to the previous 
pages to see the ad again. 
Regarding the online survey procedure, the online consumer panel members received an 
e-mail announcement containing a brief description of the study with a link to the survey. The 





old to participate according to the Institutional Research Board (IRB) protocol. The first page 
ensured the purpose of the study broadly and assured anonymity.  
By clicking the URL, the panel members directly logged on to the survey site. Subjects 
who agreed proceeded to the survey. By the survey software, subjects were randomly assigned to 
one of the manipulated treatment conditions. After answering some pre-measures including 
DTCA regulatory knowledge measures, subjects were shown an antidepressant ad on the screen. 
After viewing the ad, subjects completed manipulation check items and major dependent 
measures. At the end of the survey, basic demographic information was asked.   
 More specifically, at the pre-measure stage, the instrument first measured potential 
correlates (i.e., overall subjective health status, perceived importance of the disease, perceived 
familiarity with the disease, and previous experience with the disease) and DTCA regulatory 
knowledge. 
 Considering the artificial nature of the experiment, subjects were asked to read the ads 
the same way as they would if they were at risk of mental depression in their real life. After the 
subjects read the ad, they were asked to complete manipulation check items and dependent 





participants amounted to 2641 that is a fairly sufficient sample size for the current research 
design and the number of dependent variables. 
 A number of sources were considered to obtain a sample of adult consumers from diverse 
demographic backgrounds. A convenience sample of 264 consumers were registered members of 
the panel. The overall demographics consist of a random spread across the US. Though it was 
not specifically mirroring the US census, the sample had a diverse representation. Specifically, 
the sample represented diverse demographic background. Among the respondents (N = 264), 
63.6% were males and 36.4% were females. The respondents ranged in age from 18 to 77 years 
(M = 30.03, SD = 13.73). Among them, 43.9% were younger adults (18–44 years), 45.1% mature 
adults (45–64 years), and 11% older adults (65 years or older). The majority were whites 
(79.5%), followed by Black, not Hispanic (13.3%), Hispanic, of any race (4.5%), Asian or 
Pacific Islander (1.1%), and American Indian, Eskimo, or Aleut (.8%). 
 In terms of respondent education, 27.7% of respondents attended some college education 
1 The researcher originally collected the data from 420 individuals assigned to three conditions of disclosure 
prominence. One of them was a condition designed for an exploratory purpose to be compared with the low 
prominence condition. Since responses from the exploratory condition did not differ from the low prominence 











without degree, followed by respondents completed high school but no college education 
(25.0%), bachelor’s degree (17.8%), and associate’s degree (13.3%). The majority of 
respondents had an annual household income of $25,000 to $99,999, with 62.1% reporting. In 
addition, most respondents (87.9%) used laptop or desktop computers to participate in the 
survey. The sample of this research is illustrated in Table 2. 
 It is worthy to note that 29.9% (n = 79) of the sample reported having been diagnosed 
with clinical depression. Considering that an estimated 1 in 10 US adults reports current 
depression (Center for Disease Control and Prevention, 2010), the current study’s sample may 
over-represent the US adult population with depression experience. However, it is worth noting 
that the survey instrument of the current study asks subjects to report their previous experience 
with depression up to now. Given that the Center for Disease Control and Prevention (2010) 
reports the current depression diagnosis (approximately 10%), it is possible to speculate that 
subjects’ reported accumulative depression experience rate (approximately 30%) would be 
higher than the current depression rate reported. That is, because subjects’ response in the current 
research may represent not only current depression experience but also a whole personal history 
of depression in their lifetime. Therefore, with careful caution, the higher depression experience 
report of this research than that of the current epidemiological data seems to be understandable. 
 
Design 
 Because the current study has one manipulated categorical variable with two levels (i.e., 
high vs. low prominence) and one measured continuous variable (i.e., DTCA regulatory 





the research hypotheses (Aiken & West, 1991; Fitzsimons, 2008). The current study did not 
dichotomize the continuous DTCA regulatory knowledge levels (e.g., 0-6) into two categories 
such as high and low. Fitzsimons (2008) notes that median-splitting of a continuous independent 
variable has principal problems. First, dichotomizing continuous independent variables are likely 
to unnecessarily reduce the statistical power available to test research hypotheses (Irwin & 
McClelland, 2003). Second, a more serious potential problem is that inappropriate 
dichotomization of continuous variables can create spurious significant results if the independent 
variables are strongly correlated (Maxwell & Delaney, 1993). Third, inappropriate dichotomy of 
the data is likely to loss important information by disregarding meaningful differences among 
varying continuous levels (Fitzsimons, 2008). In this regard, Fitzsimons (2008) suggests to 
follow a guide to performing analysis including continuous independent variables and 
interactions proposed by Aiken and West (1991).  
More specifically, when there are one straightforward manipulation of independent 
variable and one measured continuous variable that is not easy to manipulate at the individual 
consumer level or not appropriate for manipulating due to its nature such as pre-existing 
cognitive traits, the researcher needs to decide whether he/she uses a continuous measure as it is, 
to capture varying levels of the measured variable (Fitzsimons, 2008). However, more often than 
not, when the researcher is interested in testing the interaction between the two independent 
variables, a common mistake committed by the researcher is dichotomizing the measured 
variable into two levels using a median-split method. However, this approach may be 
inappropriate and possibly result in misleading interpretations of the results (Fitzsimons, 2008). 





analyses to utilize the continuous nature of the measured independent variable. Further, when the 
researcher analyzes the interaction between one manipulated categorical variable and one 
measured continuous variable, the Johnson-Neyman regions of significance procedure is 
suggested as well as a simple slop analysis (Aiken & West, 1991; Preacher, Rucker, & Hayes, 
2007). For instance, the Johnson-Neyman procedure shows where the subgroups’ (e.g. high vs. 
low) regression slopes and intercepts are significantly different from one another across varying 
levels of the measured variable. The regression slopes and intercepts can be plotted in graph and 
the statistics of the method indicate the regions of significance. To further pinpoint the 
interaction pattern, the simple slope analysis allows the researcher to examine the slopes of the 
manipulated variable at each level of the measured variable. In the current research context, for 
instance, the simple slope analysis shows whether the regression slopes are significantly different 
between the two different manipulation conditions, at one standard deviation below the mean of 
the measured variable, at the mean of the measured variable, and at one standard deviation above 
the mean of the measured variable, (Aiken & West, 1991). 
When the researcher addresses moderated mediation hypotheses, the use of the simple 
slopes method and Johnson-Neyman technique are suggested as a rigorous and appropriate 
analysis approach (Preacher et al., 2007). Further, to examine the mediating hypotheses, 
asymptotic (i.e., interpreting confidence intervals) and resampling (e.g., 5,000 resamples) 
strategies for assessing and comparing indirect effects, referred to as the bootstrap approach, are 
suggested as a rigorous contemporary analysis (Preacher & Hayes, 2008). Taken together, given 
the aforementioned methodological considerations and suggestions by methodologists, the 





the simple slopes method, and the bootstrap approach are appropriate for probing the research 
hypotheses of the current research. 
 
Table 2. The Sample Profile of Study Respondents (N = 264) 
































White, not Hispanic  
Black, not Hispanic  
Hispanic, of any race  
Asian or Pacific Islander  



















Some college education but no degree  
Completed high school but no college education  
Bachelor’s degree (examples: BA, BS)  
Associate's degree (examples: AA, AS)  
Master's degree (examples: MA, MBA)  
Attended graduate school but no degree  
Did not finish high school  
Doctorate degree (examples: PhD, EdD)  


























Annual Household Income 
 
$25,000 ~ $49,999  
Lower than $25,000  
$50,000 ~ $74,999  
$75,000 ~ $99,999  
$100,000 ~ $149,999  


























Manipulation of Independent Variable: Prominence 
Pretests and Manipulation Checks 
Antidepressant ads for a fictitious brand were generated to exclude potential biases from 
prior experience or perception regarding the brand. The current study focuses on mental 
depression because it represents one prevalent but undertreated health issue among US adults 
(Gonzales, Tarraf, Whitfield, & Vega, 2010; Kessler et al., 2003; Rosenthal, Berndt, Donohue, 
Frank, & Epstein, 2002). The Centers for Disease Control and Prevention (2014) indicates that 
each year approximately 10% of US adults aged ≥ 12 years reported current depression during a 
period of 2007-2010. Examining consumers’ response to an antidepressant DTC ad will 
illuminate DTCA’s potential contribution to consumer education and public health. 
More specifically, a number of factors were considered to select the antidepressant 
DTCA category among various therapeutic categories. First, among the top 20 most advertised 
prescription drugs, mental depression is one of highly stigmatized conditions (An & Kang, 2011; 
Donohue, Cevasco, Rosenthal, 2007; Park & Grow, 2008). In this regard, understanding the 
educational value of antidepressant DTCA may provide insight into reducing social stigma 
associated with the disease category (An & Kang 2011). Second, mental depression is the most 
common form of mood disorders that deserve research attention (Park & Grow, 2008). Third, 
mental depression remains as a largely under-diagnosed and under-treated illness category 
(Holmer, 2002), which calls for consumer education to promote disease diagnosis and treatment. 
DTCA has been considered one potential health education source (Royne & Myers, 2008). 
Although approximately 10% of US adults reported their current depression during 2007-2010, 





month during the same period (National Center for Health Statistics, 2013; Health, United States, 
2012). More specifically, in terms of gender, 5.3% of male respondents reported that they have 
used antidepressants, while 11.9% have used antidepressants in past 30 days (CDC, National 
Center for Health Statistics. Health, United States, 2012). This suggests that male consumers still 
need appropriate medical treatments along with other life style remedies. Fourth, antidepressant 
DTCA is targeted at a potentially vulnerable consumers with symptoms such as feeling of social 
isolation and worthlessness (Park & Grow, 2008). Addressing this category has important social 
implications. Fifth, antidepressant treatments contribute to reduced risk of suicide (Olfson, 
Shaffer, Marcus, & Greenberg, 2003) and lower suicide rates (Gibbons, Hur, Bhaumik, & Mann, 
2006). Sixth, depressive disorders often harm social, occupational, and role functions and 
thereby have detrimental consequences on quality of life (Olfson et al., 2002). Olfson et al., 
(2002) notes that the negative effects of depression on daily function of individuals match that of 
heart disease, and exceed that of diabetes, arthritis, and peptic ulcer disease. Seventh, according 
to the Global Burden of Disease Study (Murray & Lopez, 1996), major depression is the fourth 
leading cause of worldwide disability and is speculated to become the second leading cause by 
2020. Eighth, among persons diagnosed with and receiving treatment for depression, the second 
highly used treatment method was antidepressant (75.3%) followed by physician visits (84.6%) 
(Marcus & Olfson, 2010). Considering that antidepressant DTCA spending is positively 
associated with antidepressant uses (Donohue & Burndt, 2004), addressing consumer response to 
antidepressant DTC ads will add invaluable insights into promoting depression diagnosis and the 
treatment-expanding role of DTCA (Park & Grow, 2008). 





manipulated through combining various message execution factors simultaneously based on the 
FDA’s (2009) draft guidance for pharmaceutical marketers’ risk communication. To be more 
specific, high risk disclosure prominence was operationalized as a combination of using box 
outlines (vs. running text without box lines), a larger font size (14 vs. 10), red colored texts (vs. 
black), bold type (vs. regular), bulleted texts (vs. no bullets), and proximate placement to use 
information. In contrast, to operationalize the low prominence condition, the above message 
devices were employed in opposite ways (see appendix B & C). As a result, except major health 
risks of the drug (i.e., manipulation), all other design elements were equivalent across different 
experimental conditions. Graphics were exactly the same and word counts were largely 
equivalent across the two conditions (i.e., 221 for low prominence; 227 for high prominence).  
 To secure proper manipulation, two pretests were conducted. In the first pretest, 58 
college students from a northern state university participated. In the second pretest, 59 college 
students from different state universities participated. To check whether risk disclosure 
prominence was successfully manipulated, subjects were asked to indicate on a 7-point scale (1 = 
not at all prominent, 7 = extremely prominent) their agreement with “How prominent do you feel 
was the information in the ad about the health risks of Luminexell?”  
In the first pretest, the manipulation check results and respondents’ solicited focus group 
interview were analyzed (Griffin, Babin, & Darden, 1992). The customized simple method 
contrast test results for the first pretest indicated that the manipulation of risk disclosure 
prominence was not successful, Mlow-prominence = 3.61, SD = 1.41, Mhigh-prominence = 3.81, SD = 1.47, 
difference value (estimate – hypothesized) = -.31, SE = .38, p > .05. The results were discussed 





and then the researcher determined to conduct the second pretest after revising the stimuli and 
manipulation check items. 
In the second pretest phase, two ad stimuli were generated by using professional visual 
design softwares, including Adobe Creative Cloud Indesign and Photoshop. Subjects were 
shown the ads and reported their impression about prominence of risk disclosure in the ads. A 
simple method planned contrast test was performed, using the statement “How prominent do you 
feel was the information in the ad about the health risks of Luminexell?” with endpoints of “not 
at all prominent” and “extremely prominent.” The results showed that the manipulation of risk 
disclosure prominence was successful, (Mlow-prominence = 3.27, SD = 1.49, Mhigh-prominence = 4.21, SD 
= 1.75, difference value (estimate – hypothesized) = -.94, SE = .44, p < .05. 
Based on the pretest results, in the main test the manipulation check was also conducted, 
in order to confirm the test ads were operationalized as the researcher intended. The GLM 
univariate test results showed that the manipulation of risk disclosure prominence was 
successful, Mlow-prominence = 4.41, SD = 1.60, Mhigh-prominence = 5.03, SD = 1.52, F(1, 262) = 10.43, 
p ≤ .001. The customized contrast test using the simple method confirmed that the manipulation 
was successful as the researcher intended, with the difference value (estimate – hypothesized) = -
.62, SE = .19, p ≤ .001. Taken together, these results clearly indicate the success of manipulation 
in that the comparisons between high and low prominence conditions revealed statistically 
significant perceptual difference regarding risk disclosure prominence. 
It is worth noting that the procedure of conducting the instrument of this study, including 
the positioning of each measure of constructs in the questionnaire, was carefully designed based 





1982; Keppel & Wickens, 2004; Purdue & Summers, 1986; Shadish, Cook, & Campbell, 2002). 
First, random assignment of subjects to study treatment conditions facilitates causal 
interpretation by excluding potential systematic extraneous factors (Keppel & Wickens, 2004; 
Shadish et al., 2002). In particular, manipulation and confounding checks appear to have critical 
value during the pretest/pilot test, because the cost associated with negative results at this phase 
is relatively small, whereas the cost associated with unfavorable results is high in the main 
experimental stage (Perdue & Summers, 1986). 
Among others, the timing of manipulation and confounding checks is worthy to note (i.e., 
before or after dependent measures). In general, extensive testing of the manipulations in the 
pretest phase could lessen the need for manipulation and confounding checks in the main 
experiment if this testing is conducted with the same procedures, experimental instruments, and 
subject types as the main experiment (Purdue & Summers, 1986). In this regard, the current 
research employed almost the same procedure, experimental instruments, and subject types to 
reduce variations between the pretests and main experiment. Further, the current research 
followed a widely suggested experimental procedure that runs the major experiment only after 
the manipulation checks are found to be successful in the pre-test phase. Nevertheless, to secure 
the success of manipulation in the main test, manipulation and confounding checks were also 
included in the main experiment (Kerlinger & Lee, 2000; Shadish et al., 2002).  
The reason of including such checks before dependent measures in the main experiment 
was because the researcher judged that ensuring appropriate operationalization of the 
independent variable (i.e., prominence) is critical given the FDA’s concern about risk disclosure 





health communication literature were measured before stimuli, because those constructs are 
individuals’ pre-existing cognitive traits that need to be treated as persistent characteristics rather 
than immediate responses to the experimental stimuli. Therefore, according to the consumer 
experimental convention in the literature, the current research performed the measurement of 
potential correlates before subjects were shown experimental test ads. 
In addition, the inclusion of manipulation and confounding checks before dependent 
measures can be justified based on the literature on experimental methodology. Specifically, 
research suggests that subjects should be interviewed to complete manipulation and confounding 
checks immediately after exposure to the manipulation (Aronson & Carlsmith, 1968; Purdue & 
Summers, 1986). Waiting until after the dependent variables have been assessed is likely to 
decrease the subject’s capacity to fully indicate their responses to the manipulation and could 
bias their reports (Purdue & Summers, 1986). Moreover, the researcher conducted solicited 
interviews with pretest participants as supplemental qualitative techniques (Aronson & 
Carlsmith, 1968). These methods can offer a better perspective of how the desired variance in the 
intended independent variable can be operated (Purdue & Summers, 1986). 
With regard to manipulation checks in the main experiment, although some suggest that 
dependent measures should be conducted first due to demand characteristics associated with self-
reports or other forms of obtrusive measurement (Wetzel, 1977), measuring the dependent 
variables before conducting the manipulation assessment presents a set of potential problems. 
First, when the manipulation checks come after the dependent measures, important effects of the 
manipulation could already have dissipated because the manipulation effects would be temporary 





particular, when these checks involve self-report measures, subjects’ responses to the dependent 
measures could bias their reactions to the subsequent manipulation checks (Kidd, 1976).  
In this study, the manipulation check results appeared to be significant, Mlow-prominence = 
4.41, SD = 1.60, Mhigh-prominence = 5.03, SD = 1.51, F(1, 262) = 10.43, p ≤ .001, whereas the 
confounding check did not show significant results, Mlow-prominence = 5.16, SD = 1.17, Mhigh-
prominence = 4.98, SD = 1.45, F(1, 262) = 11.26, p > .10, using the statement “How prominent do 
you feel was the information in the ad about the uses of Luminexell?” with endpoints of “not at 
all prominent” and “extremely prominent.” Although use of confounding checks has been rarely 
employed in marketing experiments despite its importance (Purdue & Summers, 1986), the 
current research utilized the confounding check and further demonstrated that the manipulation 
was successful with less concern about potential confounding. 
To address alternative insights for the ordering of manipulation checks and dependent 
measures, Kidd (1976) suggests the creation of manipulation check groups whose sole purpose is 
the assessment of manipulation success. However, Wetzel (1977) argues that the subjects in a 
pretest serve the function of Kidd’s (1976) manipulation check groups. In this study, a series of 
pretests ensuring the equivalence between the pretests and the main experiment clearly support 
the manipulation of prominence was successful, and the pattern of prominence effects on major 
dependent variables were similar, indicating that the potential problem of the ordering effects of 









Measured Independent Variable: DTCA Regulatory Knowledge 
DTCA regulatory knowledge was measured using multiple items adopted from the 
FDA’s consumer education webpage regarding prescription drug advertising, For Consumers & 
Patients (FDA, 2014). The FDA provides health information on its website for consumers to stay 
safe and healthy. On the website, consumers can obtain information by topic such as cosmetics, 
drugs, food, medical devices, and tobacco products. If consumers click on the drugs menu, they 
are linked to various information sources regarding the use of drug such as educational 
resources, buying & using medicine safely, tips for seniors, tips for parents, and prescription 
drug advertising. 
 Consumers can navigate detailed information through clicking on the prescription drug 
advertising menu from the left side navigation column. The linked page shows important and 
relevant information regarding prescription drug advertising, including the background of drug 
advertising, basics of drug ads, questions to ask yourself, and sample prescription drug 
advertisements, in order to promote general knowledge of the DTCA category. Among others, 
the page provides consumers with frequent questions and answers (Q&A) regarding prescription 
drug advertising to inform consumers about the DTCA category’s regulatory context. The 
current research borrows the DTCA knowledge measure items from the Q&A section, because it 
best represents the current FDA’s thought and consumers’ most frequent questions regarding the 
DTCA category. 
 Individuals’ DTCA regulatory knowledge has been neither measured nor controlled in 





research. The measurement of knowledge has long been a subject in the marketing literature 
(e.g., House et al., 2004; Park et al., 1994). The current research adopted a widely suggested 
approach to measure DTCA regulatory knowledge. The objective measure of DTCA regulatory 
knowledge was designed as series of six true/false items. According to previous research 
approach (Park et al., 1994), the items were selected from the FDA’s consumer education page 
through discussions with DTCA experts and from modifications of the pretest items.  
More specifically, to establish the validity of the measurement, the items were reviewed 
by professional DTCA researchers, and selected and refined to form a better measurement scale 
for the intended construct. The measure items included: (1) The FDA bans consumer-directed 
ads for prescription drugs that have serious health risks; (2) The FDA requires drug companies to 
use hard-to-understand medial language in prescription drug ads directed to consumers; (3) The 
FDA works with drug companies to create prescription drug ads directed to consumers; (4) The 
FDA approves prescription drug ads before they are seen by the public; (5) The FDA regulates 
the design of prescription drug ads directed to consumers; and (6) The FDA conducts research to 
examine consumer attitudes and behaviors toward prescription drug advertising (see Table 3 & 
4). The mean for DTCA regulatory knowledge was 2.09 (SD = 1.29), indicating an overall low 
knowledge level. A one sample t-test results shows that the average DTCA regulatory knowledge 









Table 3. Percentage of Right Answers for DTCA Regulatory Knowledge 
























































38.6% 62.1% 27.7% 20.8% 29.5% 30.3% 
 
Table 4. Descriptives for DTCA Regulatory Knowledge 






















Total 264 100 
 
Dependent Variable: Perceived Attention to Risk Disclosure 
 The measurement of attention poses a major challenge to consumer researchers. Three 
general approaches are found to have been employed in the consumer psychology literature: 
inferences based on observed behaviors, psycho-physiological techniques, and self-reports 
(Chaffee & Schleuder, 1986). To provide a foundation for the use of perceived attention to risk 
disclosure in this research, in this section prior research is reviewed with the justification of the 





 First, the behavioral observation approach has assessed the movements of people who 
were filmed while watching stimuli by carefully coding facial expressions (Ekman et al., 1972), 
by observing participants’ eye gaze or aversion during experimental presentations of messages 
(Alwitt, Anderson, Lorch, & Levin, 1980), and by measuring reaction times to a message 
(Meadowcroft & Reeves, 1985).  
 Second, in terms of the psycho-physiological measurement, experimental psychology and 
psychophysiology have examined blood pressure, galvanic skin response (Zillmann, 1982) and 
brain wave activity (Thorson, Reeves, & Schleuder, 1985). In particular, eye-tracking 
methodology has been one of the most popular approaches to measure attention. Because 
attention to advertisements cannot be directly inferred from consumers’ memory, it is useful to 
examine consumers’ actual eye (e.g., pupil) movements. Specifically, cameras track the eye and 
head position, and allow for continuous correction of position shifts. A couple of indicators of 
visual attention can be assessed including ad (i.e., entire ad page) gaze duration and ad-element 
gaze duration (Krugman et al., 1994; Pieters, 2008). Ad gaze duration is the total time that 
consumers who selected the ad, on average, spent on it, and measures how well an ad retains 
consumers in its environment. Ad-element gaze duration assesses the time spent on each of the 
ad elements (Pieters & Wedel, 2004). Eye-tracking methodologies may be promising because 
gaze can be used as a proxy measure for a consumer’s attention (Cutrell & Guan, 2007). While 
many measurement approaches of attention rely on the explicit actions of consumers such as 
mouse clicks, query streams or diary reports, eye tracking can provide more detailed moment-by-
moment observations about how consumers interact with messages (Cutrell & Guan, 2007). 





regarding attention perception. This methodological approach is employed not because it is an 
ideal method, but because for many research purposes it is the only measure available (Chaffee 
& Schleuder, 1986). In experimental effects research, correlations between objective attention 
and self-reported attention measures have been employed as a validity check (e.g., Krull & 
Husson, 1979; Reeves et al., 1985) and introspective self-observation is commonly utilized in 
survey research (Chaffee & Schleuder, 1986). 
 The above three general approaches to attention measurement have their own advantages 
and disadvantages. Although behavioral observation provides an indicator for natural attention 
setting, one cannot assume that its effects can be tested in the same way as with more closely 
attended messages. Although psychophysiological approaches offer more reliable and accurate 
measures for attention, more often than not, the resources and instruments are not available for 
researchers. Further, these approaches have limitations in providing an immediate solution to 
multivariate filed research where attention to various media is to be measured. (see Chaffee & 
Schleuder, 1986 for more information). 
 Given the foregoing review of literature on attention measurement, there are various 
ways to conceptualize and measure attention to messages. However, all these approaches are 
viewed as legitimate and valuable and methodologically the simplest way to operationalize 
attention is self-reports (Reeves & Thorson, 1986; Thorson et al., 1992). For this reason and 
given limited resources, the self-reported intensity of attention (i.e., perceived attention) is 
employed in the current research. 
  To assess the extent of subjects' perceived attention to risk disclosure prominence, a 





modified for the current study context:  “How much attention did you pay to the information 
about the health risks of Luminexell?” (1 = no attention, 7 = great attention). The mean for 
perceived attention was 5.78 (SD = 1.29) (see Table 5). Overall, subjects reported relatively high 
perceived attention. 39% (n = 103) of the sample reported “great attention.” This high number 
raises caution in interpreting the results. For instance, due to the artificial nature of experiment or 
obtrusive self-reported measure, the overall attention score could have been inflated. The overall 
frequency distribution of perceived attention was negatively skewed (skewness = -.84, SE = .15), 
indicating lack of symmetry. In addition, subjects’ reported average attention score was higher 
than the midpoint (4), using a one-sample t-test, t(263) = 22.42, p < .001. 
Dependent Variables: Recall and Recognition 
 Advertising research has employed recall and recognition as important effectiveness 
measures (Moore, Stammerjohan, & Coulter, 2005). In particular, considering that the major 
purpose of risk disclosure is to encourage consumers to utilize provided risk information in their 
decision making (Andres et al., 2009; Burton, Andrews, & Netemeyer, 2000), examining recall 
and recognition of risk information in DTCA may provide meaningful insight into consumer 
health education. In addition, research on advertising attention has measured recall and 
recognition as major criterion variables (Rosbergen et al., 1997). 
In general, the most widely employed two memory measures in advertising research are 
unaided-recall that is an open-ended question, and aided-recognition measure that provides a list 
of choices to allow respondents to indicate whether each choice was presented in the ad 
(Rosbergen et al., 1997). In this research, the recall test was an open-ended question asking 





recall test statement read “The ad presented the health risks of Luminexell. In the box below, 
please write all the health risks of Luminexell you can recall from the ad. (Lynch & Srull, 1982)” 
To appraise recognition, subjects were provided with a checklist that presents a list of ten health 
risks. Five of which were the health risks of the drug presented in the ad, and the remaining five 
of which were "distracter" (false) health risks that were not presented in the ad (Davis, 2010; 
Lynch & Srull, 1982). The order of health risks were randomized using the Qualtrics software 
feature. The number of explicitly right answers for the recall test was coded by the researcher. In 
the same vein, the number of right answers for the recognition test was coded. For both 
measures, one right answer counted one point and the points were summed to form a composite 
score for each memory construct. 
 
Table 5. Descriptives for Perceived Attention 






















Total 264 100 
 
It is worth noting that the current research especially uses a recognition task to assess 
explicit memory retrieval because recall performance is generally reported as low (Shapiro & 
Krishnan, 2001). To maximize the measurement validity, two methods were utilized. First, ten 





researcher considered whether the subject accurately or randomly chose the answer. To do so, 
when the subject indicated “yes” for the presented health risk, the researcher gave one point. 
Furthermore, to prevent inaccurate and biased random choice, when the subject indicated “no” 
for the health risk that was not presented (i.e., distractor), the subject was also given one point. 
However, when subjects failed to accurately recognize whether a particular health risk was 
shown in the ad, they did not obtain points. When the subject chose “don’t know” or a wrong 
answer, the answer was given 0. As a result, when the subject correctly answered for all choices, 
his/her score could add up to 10, whereas when the subject’s all answers were wrong or 
ambiguous (i.e., don’t know), the score could be 0. The summed single composite score for 
recognition measure was reliable (Cronbach’s α = .79). The mean for the recognition score was 
5.64 (SD = 2.88), indicating an overall high performance. 5.3% (n = 14) scored 0, whereas 
10.2% (n = 27) scored 10 (see Table 6). 
On the other hand, the recall score was coded by the researcher. When the subject 
reported explicitly correct health risk names that were presented in the ad, each correct answer 
was given one point. Therefore, when the subject correctly answered for all the five health risks 
presented in the ad, his/her score could add up to 5, whereas when he/she provided no right 
answers at all, his/her score could be 0. The mean for the recall score was 1.07 (SD = 1.16), 
indicating an overall low retrieval performance. Approximately 40% (n = 105) of the sample 
scored 0 (see Table 7). Whereas the recognition score was appropriate for calculating 
measurement reliability (internal consistency), the recall score was not appropriate for 
calculating a coefficient value. Further, given that only explicitly correct answers were coded as 






Table 6. Descriptives for Recognition 


































Total 264 100 
 
 
Table 7. Descrptives for Recall 























 Several potential covariates of consumer response to DTCA were identified from the 
DTCA literature and measured to be controlled and to exclude alternative explanations of the 





pre-existing cognitive traits could affect consumer response to DTCA (e.g., An, Jin, & Brown, 
2009, Park et al., 2013; Ju & Park, 2013), including current health status, subjective familiarity 
and perceived importance of a disease, and personal experience with a disease. Such cognitive 
variables are known to increase or decrease personal involvement with health product advertising 
information (An et al., 2009; Park et al., 2013). Therefore, the current research attempted to 
account for the influences of such variables. Specifically, subjects indicated on a four-point scale 
(1 = poor, 2 = fair, 3 = good, and 4 = excellent) how they rated their overall health at the present 
time (M = 2.69, SD = .74) (An et al., 2009; Park et al., 2013; Ju & Park, 2013). Perceived familiarity 
with depression was measured on a seven-point scale (1 = not at all familiar, 7 = very familiar; M 
= 4.62, SD = 1.72) (Ju & Park, 2013). According to a DeLorme, Huh, and Reid’s (2009) analytical 
approach, to test whether or not this mean score was significantly different from the mid-point, a 
one sample t-test was conducted with the mid-point (4) as a test value. The results indicated 
significant difference (t = 5.83, df = 263, p < .001). Perceived importance given to depression was 
assessed on a seven-point scale (1 = not at all important, 7 = very important; M = 4.81, SD = 1.78) 
(Laffrey & Isenberg, 1983; Ju & Park, 2013). To test whether or not this mean score was 
significantly different from the median point, a one sample t-test was conducted with the mid-point 
(4) as a test value. The results indicated significant difference (t = 7.43, df = 263, p < .001). Prior 
experience with depression was measured using yes/no response options (An et al., 2009; Park & 
Grow, 2008; Park et al., 2013; Ju & Park, 2013). About 30% of subjects reported having been 
diagnosed with depression. These potential covariates were submitted to regression analyses for 
their potential influence on dependent variables to be controlled (Hair, Anderson, Tathan, & Black, 





general, their subjective (perceived) knowledge about clinical depression was measured (M = 4.32, 
SD = 1.67). A one sample t-test was conducted with the mid-point (4) as a test value. The results 
indicated significant difference (t = 3.13, df = 263, p < .01). The results from a series of t-tests 
imply that subjects of the current research have a reasonably good understanding of what clinical 






CHAPTER 4: ANALYSIS AND RESULTS 
Analysis Approach 
To analyze the data, descriptive and inferential statistics were utilized. In terms of 
descriptive statistics, correlations among the major study variables are summarized along with 
means and standard deviations in Table 8. To test the main and interaction effect hypotheses, the 
current research employs a series of multiple regressions. In particular, because DTCA 
regulatory knowledge was measured using a quantitative composite score, regression analysis 
helps the researcher prevent from unnecessary loss of information and statistical power due to 
dichotomizing the knowledge level into a few categorical groups (Fitzsimons, 2008). In addition, 
to further pinpoint the patterns of interaction between DTCA regulatory knowledge and 
prominence on dependent variables, regression slopes and intercepts for each subgroup (high 
prominence vs. low prominence) were interpreted. Specifically, the Johnson-Neyman’s 
significance region procedure and simple slop analysis were performed to see where the 
significant prominence effects exist among varying levels of DTCA knowledge. As to the 
mediation tests, this research employs the bootstrap approach because the method is suggested as 
a superior approach to the traditional Baron and Kenny method (Preacher & Hayes, 2004, 2008; 










Table 8. Inter-Correlations among Major Variables of Study 





1. Prominence 1     
2. DTCA Knowledge -.006 1    
3. Perceived Attention .186** .207** 1   
4. Recall .167** .027 .267** 1  
5. Recognition .220** .083 .379** .437** 1 
Note: ** Significant at .01  
 
The Results of Hypothesis Tests 
Hypotheses 1 through 6: Prominence and DTCA Knowledge Main Effects 
 To examine the hypotheses 1-6, moderated hierarchical analyses were used. As a check 
for multicollinearity, the researcher calculated variance inflation factor (VIF) scores for all 
variables in each regression model. As shown in Table 9, 10, and 11, all VIF scores were less 
than 2, suggesting that muticollinearity was not a serious problem in the analysis (Oke, 
Walumbwa, & Meyers, 2012). To control potential correlates, gender, age, education, and 
household income were entered as general demographic control variables at Step 1. Then, the 
correlates of consumer response to the DTC ad identified in the literature were submitted at Step 
2, including overall health status, perceived familiarity, perceived importance, and prior 
experience. At Step 3, prominence and DTCA regulatory knowledge were entered. Finally, the 
prominence × DTCA regulatory knowledge interaction was entered at Step 4. List-wise deletions 
accounted for missing values. 
 Table 9 summarizes the results of the regression on the extent of perceived attention. The 
results showed that risk disclosure prominence had significant effects on perceived attention (b = 





effects on perceived attention (b = .281, SE = .072, p < .001), supporting H4. 
The same procedure was used to examine the prominence main effects on recall. To 
control potential correlates, gender, age, education, and household income were entered as 
general demographic control variables at Step 1. Then, the correlates of consumer response to the 
DTC ad identified in the literature were submitted at Step 2, including overall health status, 
perceived familiarity, perceived importance, prior experience. At Step 3, prominence and DTCA 
regulatory knowledge were entered. Finally, the prominence × DTCA regulatory knowledge 
interaction was entered at Step 4. List-wise deletions accounted for missing values. 
 
Table 9. Moderated Hierarchical Regression on Perceived Attention (N = 264) 
 Statistics 
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Note. Adjusted R2 = .116, *p < .05, **p < .01, ***p < .001  
 
  
Table 10 summarizes the results of the regression on the extent of risk information recall. 





disclosure recall (b = .161, SE = .166, p > .05. The results did not support H2. In the same vein, 
DTCA knowledge did not have significant effects on risk disclosure recall (b = -.011, SE = .064, 
p > .05). H5 was not supported. 
 
Table 10. Moderated Hierarchical Regression on Recall (N = 264) 
 Statistics 
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Note. Adjusted R2 = .067, **p < .01  
 
The same procedure was used to examine the prominence main effects on recognition. To 
control potential correlates, gender, age, education, and household income were entered as 
general demographic control variables at Step 1. Then, the correlates of consumer response to the 
DTC ad identified in the literature were submitted at Step 2, including overall health status, 
perceived familiarity, perceived importance, prior experience. At Step 3, prominence and DTCA 
regulatory knowledge were entered. Finally, the prominence × DTCA regulatory knowledge 
interaction was entered at Step 4. List-wise deletions accounted for missing values. 





recognition. The results showed that risk disclosure prominence had significant effects on risk 
disclosure recognition (b = 1.374, SE = .432, p < .01, supporting H3. In the same token, DTCA 
regulatory knowledge had significant effects on risk disclosure recognition, supporting H6. 
 
Table 11. Moderated Hierarchical Regression on Recognition (N = 264) 
 Statistics 
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Note. Adjusted R2 = .067, **p < .01  
 
Hypotheses 7a, 7b, and 7c: Moderating Effects of DTCA Regulatory Knowledge 
 As shown, in the previous sections, moderated hierarchical regressions on perceived 
attention (see Table 4), recall (see Table 5) and recognition (see Table 6) were performed. 
Among the three criterion variables, DTCA regulatory knowledge was found to positively 
moderate the effects of risk disclosure prominence on perceived attention. The block including 
the prominence × DTCA regulatory knowledge was associated with a significant increase in 
explained variance in perceived attention (∆R2 = .016, p < .05), supporting H7a. However, the 






Specifically, according to Aiken and West (1991), to assess possible prominence 
differences in both the intercept and slope for prediction of the extent of perceived attention, the 
moderated hierarchical regression was performed to predict perceived attention from prominence 
(dummy coded 1 = high, 0 = low), DTCA regulatory knowledge, and a product term to represent 
a prominence-by-DTCA regulatory knowledge interaction. The overall regression was 
statistically significant, and explained a fair proportion of the variance in perceived attention, R = 
.391, adjusted R2 = .116, F (11, 252) = 4.143, p < .001. Further, the interaction between 
prominence and DTCA knowledge was statistically significant, with b = -.606, t (252) = -2.213, 
p < .05. The regression equations to predict perceived attention from DTCA regulatory 
knowledge were as follows: 
High prominence subgroup: 5.83 + .09 × DTCA Regulatory Knowledge 
Low prominence subgroup: 4.85 + .33 × DTCA Regulatory Knowledge 
 
 These two regressions are graphed in Figure 2. High and low prominence risk disclosures 
did not considerably differ among high DTCA regulatory knowledge consumers, whereas among 
low DTCA regulatory knowledge consumers’ perceived attention was considerably higher in 
response to high prominence risk disclosure. In addition, the predicted perceived attention 
increase for low prominence (.33) was higher than the predicted perceived attention increase for 
high prominence (.09). This shows that as knowledge increases, the difference in the level of 
attention between low knowledge and high knowledge groups will decrease. The predicted 
perceived attention increase per DTCA regulatory knowledge was 0.24 higher for low 





A simple slopes analysis confirms this pattern. When knowledge was low (corresponding 
to one standard deviation lower than the mean), and medium (corresponding to the mean), the 
high prominence condition led to a higher level of attention (p < .05), whereas it did not when 
knowledge was high (p > .05). Application of the Johnson-Neyman technique shows that the 
difference between high and low prominence conditions would be significant when DTCA 
knowledge was 2.50 or lower on the five-point scale. These patterns of slopes and intercepts 
support the hypothesized main effects of prominence and moderating role of DTCA knowledge 
on perceived attention to risk disclosure (Aiken & West, 1991). Therefore, H7a was supported. 
The main and moderating effect hypotheses are summarized in Table 12. 
Hypotheses 8, 9, and 10: Mediating Effects of Perceived Attention 
 Hypotheses 8, 9, and 10 suggested that perceived attention would mediate the effects of 
prominence, DTCA knowledge, and their interaction on consumer memory of risk information, 
including recall and recognition. In particular, H10 represents a mediated moderation 
relationship. A mediated moderation refers to the extent to which an intervening variable 
mediates the effect of a more distal independent variable at different levels of the moderator 







Figure 2. Prominence × DTCA Regulatory Knowledge on Perceived Attention 
 
 To examine the hypothesized mediations, the researcher adopted the bootstrap approach 
outlined by Preacher and Hayes (2004). The bootstrapping method is similar to the Sobel (1982) 
test, but is suggested as a superior alternative if raw data are available (Homburg, Wieseke, & 
Bornemann, 2009). Further, Zhao, Lynch, and Chen (2010) note that in testing the significance 
of an indirect effect between predictors and criterion variables, the bootstrap approach is more 
rigorous and powerful than Sobel. The researcher estimated the indirect effects of the predictors 
through the mediator variable on the dependent variables and repeated the sampling 5000 times 
(Zhao et al., 2010). To secure consistency between the main effect and mediation tests, the same 






Table 12. Summary of the Main and Moderating Effect Hypotheses 
Hypotheses 
 
Predictors Outcomes Results 





























Prominence × DTCA Knowledge 
Prominence × DTCA Knowledge 
Prominence × DTCA Knowledge 








 According to the suggested steps by Zhao et al. (2010) for mediation analysis, the 
mediating role of perceived attention was denoted as (a × b) and the direct effects of independent 
variables on dependent variables were denoted as (c) with a 95% confidence interval (CI), along 
with 5000 bootstrap samples. 
 First, to examine the mediating role of perceived attention between prominence and 
recall, variables were submitted to the Preacher-Hayes (2008) bootstrap macro in SPSS 21. In the 
first analysis, the IV was prominence and the mediating variable (M) was perceived attention. 
The DV was recall score. The results showed that perceived attention had indirect-only 
mediation effects (a × b = .08) between prominence and recall, with a 95% CI excluding zero 
(.0144 to .1704). The direct effect c (.14) was not significant (p > .05). This indirect-only 
mediation overlaps with Baron and Kenny’s (1986) full mediation (Zhao et al., 2010). The 
results support H8a.  





attention had complementary mediation effects (a × b = .31) between prominence and 
recognition, with a 95% CI excluding zero (.0483 to .6374). The direct effect c (.75) was 
significant (p < .05). Specifically, a × b × c (.23) was positive, suggesting a complementary 
mediation (Zhao et al., 2010). The complementary mediation indicates that researchers need to 
consider the likelihood of an omitted mediator in the direct path, even though the hypothesized 
mediator was identified consistent with the researcher’s theoretical framework. The 
complementary mediation overlaps with Baron and Kenny’s partial mediation (Zaho et al., 
2010). Further, complementary mediations have been referred to as “consistent” models or 
“positive confounding” (Shrout & Bogler, 2002), From the bootstrap perspective, the results of 
this study support H8b, while suggesting consideration of a possibly omitted mediator in the 
direct path between prominence and recognition. 
To test H9a and H9b, the same approach was employed on recall and recognition. The 
independent variable was DTCA knowledge, perceived attention was a mediator, and recall and 
recognition were dependent variables. The results showed that perceived attention had indirect-
only effects (a × b = .04) between DTCA knowledge and recall, with a 95% CI excluding zero 
(.0135 to .0786). The direct effect c (-.03) was not significant (p > .05). H9a was supported. 
As to recognition, the results showed that perceived attention had indirect-only effects (a 
× b = .19) between DTCA knowledge and recognition, with a 95% CI excluding zero (.0545 to 
.2911). The direct effect c (.04) was not significant (p > .05). H9b was supported. 
Finally, to test H10a and H10b, the interaction term of prominence and DTCA 
knowledge (IV) was entered in the bootstrap macro with perceived attention (M) and recall and 





.13) between the interaction of prominence and DTCA regulatory knowledge, and recall, with a 
95% CI excluding zero (-.2941 to -.0194). The direct effect c (.29) was not significant (p > .05). 
These results indicate that the interaction of prominence and DTCA regulatory knowledge had 
significant interaction effects through perceived attention on recall. To pinpoint the moderated 
mediation pattern, the Johnson-Neyman method was employed. The results showed that when 
DTCA regulatory knowledge was one standard deviation (SD) below the mean (.0409 to .2675) 
and was the mean (.0165 to .1630), perceived attention mediated the prominence effects on 
recall, with a 95% CI excluding zero. However, when DTCA regulatory knowledge was plus one 
SD from mean, the mediating effects of perceived attention was not significant, with a 95% CI 
including zero (-.0673 to .0989). These results supported H10a (moderated mediation). 
The same procedure was performed on recognition. To test H10b, the interaction term of 
prominence and DTCA regulatory knowledge (IV) was entered in the bootstrap macro with 
perceived attention (M) and recognition (DV). The results showed that perceived attention had 
indirect effects  (a × b = -.47) between the interaction of prominence and DTCA regulatory 
knowledge, and recognition, with a 95% CI excluding zero (-.9906 to -.0759). The direct effect c 
(-.48) was not significant (p > .05). These results indicate that the interaction of prominence and 
DTCA regulatory knowledge had significant interaction effects through perceived attention on 
recognition. To pinpoint the moderated mediation pattern, the Johnson-Neyman method was 
employed. The results showed that when DTCA regulatory knowledge was one standard 
deviation (SD) below the mean (.1554 to 1.0272) and is the mean (.0554 to .6201), perceived 
attention mediated the prominence effects on recognition, with a 95% CI excluding zero. 





of perceived attention were not significant, with a 95% CI including zero (-.2712 to .3793). 
These results supported H10b (moderated mediation). The mediation test results are summarized 
in Table 13. 
 
Table 13. Summary of the Bootstrap Mediation Test Results 











Prominence × DTCA Knowledge 


























CHAPTER 5: DISCUSSION 
Summary of Major Findings 
The current research addresses how consumers’ DTCA regulatory knowledge and 
varying levels of risk disclosure prominence affect consumers’ risk disclosure coping strategies 
directly. Further, this research examines how DTCA regulatory knowledge moderates the risk 
disclosure prominence effects on consumers’ perceived attention to and memory of risk 
information. DTCA regulatory knowledge was found to affect how consumers process risk 
information from DTC ads. The findings illuminate the dynamic mechanisms of consumer risk 
disclosure processing, and thereby inform how fair balance can be understood from the 
consumer perspective. This research suggests that risk disclosure prominence may work 
differently depending on varying levels of consumer knowledge about the role of FDA for 
DTCA. This has an important consumer education and public health implications because 
consumes’ informed health decisions can be affected by DTCA regulatory knowledge. This 
research reveals that simply focusing on risk disclosure provision in DTCA may fail to 
illuminate true risk communication effectiveness. 
In addition, pharmaceutical marketers could benefit from the findings of the current 
research because understanding in which conditions the message prominence effects are 
enhanced or reduced provides important insight into the advertising segmenting and design. 
From the consumer education perspective, the current research findings imply that consumer 
marketplace knowledge should be an important consideration in their health decision making and 
therefore the FDA and pharmaceutical marketers may need to exert more efforts to promote 





DTCA. In particular, consumers’ capacity to recognize important health risk information was 
significantly improved when DTCA regulatory knowledge was high. When the DTCA regulatory 
knowledge level was low, more prominent risk disclosure was more effective. 
As has been well-documented, risk disclosure availability is critical in consumers’ health 
decision making (e.g., Kavadas et al., 2007; Mazis & Staeliln, 1982; Stewart & Martin, 2004). 
However, the DTCA literature has underexplored how varying levels of DTCA regulatory 
knowledge affect such decisions. Despite the severe controversy over DTCA for the last decades, 
a dearth of research on consumers’ cognitive processing of risk disclosure in DTCA might have 
led to an incomplete view of the impact of DTCA on consumers. From the public health 
perspective, identifying a way of more effective risk disclosure provision has importance. On the 
pharmaceutical marketer’s end, it could be possible through enhancing risk disclosure 
prominence. On the consumer’s end, sound health decision making using DTCA can be 
improved through enhancing DTCA regulatory knowledge. Taken together, those involved in 
DTCA practice and consumer education can benefit from consumer-oriented information 
processing principles (Boush et al., 2009; Mazis & Staelin, 1982; Richard, 1990). 
 In seeking to advance our understanding of consumer information processing mechanism 
of risk disclosure, this research also attempts to investigate a mediating cognitive factor (i.e., 
perceived attention) between DTCA regulatory knowledge and memory as well as between 
prominence and memory. In doing so, this research shows that both consumer and message 
factors can contribute to enhanced consumer involvement in risk disclosure processing. By 
testing different levels of DTCA regulatory knowledge and risk disclosure prominence, this 





DTCA risk disclosure need to take such consumer and message factors into account.  
 Overall, the findings of this research supports the theoretical premise that consumer 
responses to the ad are affected by varying levels of DTCA regulatory knowledge and risk 
disclosure prominence. Specifically, highly knowledgeable consumers were more likely to 
memorize important health risks from the DTC ad in general. On the other hand, prominent 
disclosure was more effective among less knowledgeable consumers, indicating that message 
effects could vary depending on consumers’ individual differences in cognitive variables (e.g., 
Petty & Cacioppo, 1986; Petty & Cacioppo, & Shumann, 1983). Improved recall and recognition 
scores clearly show that high levels of consumer literacy about the FDA’s regulatory role for 
DTCA play a role in consumers’ health information coping strategies. 
Before discussing the implications of the research findings in more detail, the major 
findings are summarized as follows: (1) higher DTCA regulatory knowledge enhanced consumer 
attention to and recognition of risk information in the DTC ad; (2) DTCA regulatory knowledge 
moderated the prominence effects such that among less knowledgeable consumers the 
prominence effects were maximized, whereas the effects were minimal among more 
knowledgeable consumers; (3) higher prominence were more effective for attention and 
memory; (4) DTCA regulatory knowledge and prominence effects operated through perceived 
attention on consumer memory of risk information. Taken together, the overall findings support 
the current study’s theoretical framework. In the following sections, the theoretical, managerial, 







 The present research contributes to the theory of DTCA in several ways. In general, more 
prominent risk disclosure enhances consumer memory of information and thereby could reduce 
errors and biases in consumer decision making (Andrews, 2011). Given this, prominent risk 
disclosure provision could counterbalance potential misperception about health risks of the 
product use (Kozup, Creyer, & Burton, 2003). For instance, Andrews, Netemeyer, and Burton 
(2009) found that prominently presented disclosures contribute to reducing misleading 
perceptions about ad nutrition disclosures. Therefore, consumers need to be informed about 
important product’s attributes including benefit and risk information, through prominent 
information presentation, so that they can make informed health decisions.  
However, are the prominence effects always consistent? In the current research, DTCA 
regulatory knowledge was found to not only moderate such effects but also directly affect 
consumers’ coping strategies of risk disclosure in DTCA. This is an interesting finding in that 
prior research has exclusively examined the role of general health literacy regarding consumer 
health information processing (e.g., Baer, Allen, & Braun, 2000; Wolf, Davis, Tilson, Bass, & 
Parker, 2006; Kickbusch & Ratzan, 2001). DTCA regulatory knowledge has been largely 
ignored in the literature despite its potential consequences on consumer response to the ad. 
A few DTCA studies have examined the role of consumers’ subjective knowledge about 
health and medicine in general (e.g., An, 2007). However, DTCA regulatory knowledge may 
represent a distinct aspect of consumers’ cognitive structure regarding prescription marketplace. 
While research on health literacy focuses more on particular health issues (Chang, 2008; Jorm, 





consumers’ marketplace persuasion knowledge as a DTCA persuasion coping strategy. 
In this regard, Friestad and Wright (1994) propose that marketplace beliefs consist of 
three broad knowledge dimensions including topic knowledge, agent knowledge, and persuasion 
knowledge. Among the three, in the current research, DTCA regulatory knowledge was 
conceptualized as consumers’ persuasion knowledge about the FDA’s regulatory role for DTCA. 
It is possible that some may conceptualize DTCA regulatory knowledge as agent knowledge, 
because it may also represent consumers’ awareness of how pharmaceutical advertisers must 
comply with the FDA regulation. However, beyond such classification, a more important point 
of DTCA regulatory knowledge may be that such marketplace knowledge enables consumers to 
recognize, analyze, interpret, evaluate, and remember persuasion attempts, and to select and 
execute coping tactics regarding DTCA health claims, including benefit and risk information 
(Boush et al., 2009; Friestad & Wright, 1994). In this sense, borrowing from the term used by 
Friestad and Wright (1994), this research views DTCA regulatory knowledge as health 
consumers’ DTCA health information coping strategy. Although various types of marketplace 
knowledge can be conceptualized and operationalized, this study is one of the first steps to 
empirically examine the conceptual framework of PKM in the context of DTCA. 
In addition, the moderating role of DTCA regulatory knowledge on the prominence 
effects deserves attention. The regression slope analyses clearly support the theoretical prediction 
of the current research on the interactive relationship between DTCA regulatory knowledge and 
prominence on consumer response to the ad. As DTCA regulatory knowledge increased, the 
prominence effects became less significant, whereas as DTCA regulatory knowledge decreased 





that although prominence has an impact on consumer attention to and memory of risk 
information in general, the effects would be more significant among less knowledgeable 
consumers than more knowledgeable consumers. As discussed, high DTCA regulatory 
knowledge consumers are more likely to easily locate and utilize risk information from DTCA, 
and therefore they are less likely to be affected by message presentation formats such as 
prominence. However, low DTCA regulatory knowledge consumers are less likely to easily 
locate and process less prominent risk disclosure, and therefore their attention and memory 
performance will largely hinge on the extent of risk disclosure prominence. This implies that 
information presented in the way to reduce cognitive efforts (e.g., high prominence) are more 
likely to be easily picked out and utilized by low DTCA regulatory knowledge consumers. 
However, when risk disclosure was presented less prominently, low DTCA regulatory 
knowledge consumers’ information retrieval performance was significantly lower than when risk 
disclosure was presented more prominently. 
The focus on consumer memory of this research also has a theoretical implication. The 
current research addresses important risk disclosure objectives outlined by prior research. Wilkie 
(1985) identified nine specific objectives that should be considered in designing risk disclosure: 
(1) legibility, (2) prominence, (3) attention value, (4) changing consumer awareness, (5) 
changing consumer beliefs, (6) personalizing consumer beliefs, (7) changing consumer attitudes, 
(8) changing consumer intentions, and (9) changing consumer behavior. The current research 
especially addresses three aspects of consumer response to risk disclosure information: 
prominence, attention value, changing consumer awareness. In particular, memory represents 





Additionally, the unique contribution of this research to the DTCA literature is that this 
study addresses an under-examined aspect of risk disclosure processing, through investigating a 
consumer-side factor: DTCA regulatory knowledge. The above nine risk disclosure objectives 
may not be easily achieved without considering consumers’ individual differences in cognitive 
structure given the considerable influence of such factors in consumer information processing. 
Depending on varying consumers’ cognitive schemas, the risk disclosure effects may vary 
considerably. Based on this, understanding the conditions in which the disclosure effects can be 
enhanced or reduced, should be considered an important research initiative. 
This research also shows that the DTCA literature can benefit from borrowing 
information processing theories (e.g., Deshpande & Krishnan, 1981; Mazis & Staelin, 1982). 
Despite the potential usefulness of information processing theory in designing consumer 
disclosure programs (Jacoby & Small, 1975; Wilkie & Gardner, 1974), little empirical research 
has applied and examined the utility of information processing theory with regard to risk 
disclosure effects to date in the DTCA context. Recently, some researchers shed new light on the 
importance of information processing theory in the context of DTCA research (e.g., Davis & 
Meader, 2009, Davis, 2010; Macias & Lewis, 2006; Macias et al., 2007, 2010). The current 
research further suggests that more research needs to be conducted using various theoretical 
perspectives and various cognitive variables to better understand consumers’ risk disclosure 
processing. 
 In closing this section, simply providing risk disclosure to consumers may be insufficient 
because consumers should be able to access and process the information properly. The notion of 





by the extent to which consumers are knowledgeable about the information category rather than 
the content itself. Researchers should examines which cognitive factors can affect risk 
information processing. In this sense, while the current research found significant prominence 
effects in consistent with previous research findings, more interesting findings may be the direct 
and moderating effects of DTCA regulatory knowledge on consumer memory of risk 
information.  
Finally, one intriguing future research will be on whether higher levels of DTCA 
regulatory knowledge could always promote consumers’ sound health decisions. The cognitive 
inference literature notes that in some cases consumer expertise may lead consumers to ignore 
important information from the environment due to over-confidence (Alba & Hutchinson, 1987). 
This implies that high levels of knowledge will not be always beneficial for information 
processing. Given that consumers’ knowledge calibration could be distorted by over-confidence, 
inaccurate self-knowledge calibration would impede sound health decisions. In this case, even 
though important risk information is presented prominently, highly knowledgeable consumers 
are likely to disregard it. Researchers describe this phenomenon using a term “a U-tern 
relationship” between knowledge levels and consumer information processing accuracy 
(Kavadas et al., 2007; Stewart & Martin, 2004). Because addressing this inquiry goes beyond the 
current research scope, future research needs to illuminate this theoretical curiosity. 
 
Managerial Implications 
 The current research provides practical insights into the design and target segmenting of 





could lead to disproportional effects on consumer memory of information (Cowley & Barron, 
2008), DTC advertisers need to identify optimized levels of prominence when they develop the 
design of risk disclosure in DTC ads. For instance, when advertisers present product attribute or 
efficacy information, it has been known that more prominent messages are superior to less 
prominent ones in term of consumer recall and evaluations (Gupta & Lord, 1998).  
However, based on the current research findings, it is hard to say that more prominent 
information provision is always the best policy for advertisers. Marketers should consider 
relevant consumer characteristics to achieve the intended marketing goals (Cowley & Barron, 
2008). Although information prominence increases consumer memory in general, under specific 
circumstances prominence may have a minimal impact on consumer evaluations of brands (van 
Reijmersdal, 2009).  
How can DTC advertisers achieve the intended marketing goals (e.g., market volume 
expansion), while simultaneously complying the FDA regulation? The two-sided message 
literature suggests useful insights. Two sided message refers to the message that presents both 
positive and negative information about the product (Crowley & Hoyer, 1994). Once well-
executed, two-sided messages can enhance source credibility (Eisend, 2006, 2010), and such 
enhanced credibility can increase overall persuasiveness of the messages (Wilson & Sherrell, 
1993).  
Given reportedly prevalent consumer skepticism in contemporary marketplace (Boush et 
al., 2009; Obermiller & Spangenberg, 1998), rightly provided risk disclosure may offset the 
negative impression of the product. Specifically, attribution theory suggests that individuals 





regard, acknowledging potential health risks of the drug in ads may positively contribute to 
consumer evaluations of the drug and advertiser, because it can be perceived as complying with 
the regulation and thereby as credible.  
In particular, when consumers’ DTCA regulatory knowledge is high, fair balance 
between benefit and risk information would be more beneficial for pharmaceutical advertisers. 
This is because most consumers nowadays recognize that DTCA is required to present health 
risks of the drug in ads by law. Eisend (2006) notes that consumers’ perceived marketer 
compliance to law can positively affect advertising evaluations. Therefore, advertisers need to 
comply with the DTCA fair balance requirement not only to avoid legal and ethical accusations, 
but also to achieve more favorable consumer reactions. Given that the major marketing goal of 
DTCA is to expand prescription volume, fair balanced DTCA can contribute to such marketing 
goals, while simultaneously contributing to social responsibility. Currently, this research 
phenomenon is not fully examined. More empirical research should provide solid evidence 
regarding this theoretical prediction in order to provide practical insights. 
 
Consumer Education and Public Health Implications 
  The findings of this research also address consumer education and public health 
implications. The risk disclosure requirement is based on the assumption that consumers are able 
to access and process, and thereby weigh the risks appropriately to make informed health 
decisions (Calfee, 2002; Cox et al., 2010). However, an important question remains regarding 
how well consumers utilize risk information in the DTC ad. Given that DTCA serves as an 





First, information about the drug's risks as well as benefits should be attended 
sufficiently, in order to render them to be stored and retrieved appropriately when consumers 
make health decisions. However, concerns about consumers' proper use of health information in 
DTCA call for a more meticulous examination about not only the way information is delivered, 
but also how consumer factors affect information processing (Mackert, 2011). It is worth noting 
generally accepted communication process models such as Mcguire’s (1976) steps in 
information processing (i.e., exposure, attention, comprehension, attitude, retention, retrieval, 
decision making intentions, and behavior). Recently, Wogalter (2006) refined the McGuire’s 
classical information processing model and proposed the communication-human information 
processing (C-HIP) model in the context of risk communication. Based on these information 
processing models, the point is clear. A message sent by the advertiser is not always interpreted 
by the receiver as the sender intended. To better understand this discrepancy, taking consumer 
perspectives into account can provide insight into how risk information can be more effectively 
communicated (Davis, 2010; Davis & Meader, 2009; Hoek et al., 2011; Mantel, 2010; Menon, 
Deshpande, Perri III, & Zinkahn, 2003a, 2003b). Among others, researchers are advised to 
examine consumers’ varying cognitive structures to enhance risk communication effectiveness. 
Despite the severe debate over the DTCA category, if relevant and timely health risk 
information can be conveyed to health consumers, DTCA can contribute to public health as an 
important health education source (Kaphingst & Dejong, 2004; Royne & Myers, 2008). 
However, the current research shows that the use of risk information from DTCA largely hinges 
on consumers’ DTCA regulatory knowledge. When consumers have certain levels of DTCA 





majority of consumers do not have sufficient DTCA regulatory knowledge, the importance of 
prominent risk disclosure provision increases. Considering the relatively low consumer DTCA 
regulatory knowledge level in the current research sample, the current FDA’s concern about risk 
disclosure prominence may be reasonable. 
However, in the long term, the current research findings suggest that consumer education 
by the FDA and pharmaceutical advertisers may play a promising role for consumers’ informed 
health decision making. Hoy and Andrews (2004) note that consumer education by government 
agencies, industry trade associations, and consumer advocacy groups can help consumers better 
understand complicated ad information. In this regard, the FDA and pharmaceutical 
manufacturers’ voluntary association (PhRMA) have exerted efforts to improve consumers’ 
perception and behavior regarding DTCA. However, the current research suggests that consumer 
education about the FDA’s regulatory role for DTCA may also help consumers better cope with 
risk disclosure information in DTCA.  
In some sense, DTCA regulatory knowledge can be viewed as consumers’ media literacy 
as part of overarching marketplace persuasion knowledge. Extending the PKM perspective 
(Friestad & Wright, 1994), consumers’ enhanced media literacy about DTCA may improve their 
DTCA health information coping strategies. In particular, greater DTCA regulatory knowledge 
will improve consumer processing of important health risk information of the prescription 
medicine. 
As the current research adopts DTCA regulatory knowledge measures from the current 
FDA’s webpage, the FDA can provide useful health and media literacy programs on its website 





only health education but media literacy improvement. In the same manner, consumers can also 
obtain a lot of useful educational information from pharmaceutical advertisers’ promotional 
websites and various public educational sources. In particular, the Internet serves as an important 
health information source (Dutta-Bergman, 2004; Lee, Park, & Widdows, 2009; Suggs, 2006). 
Consumer health and media literacy programs should be executed through various media 
channels. 
Unfortunately, current levels of public understanding of the FDA's regulatory role for 
DTCA appeared to be low. Bell, Kravitz, and Wilkes (1999) and Wilkes, Bell, and Kravitz 
(2000) examined what assumptions consumers make about the regulation of DTCA. The results 
(Wilkes, Bell, & Kravitz, 2000) showed that half of respondents believed that DTCA had to be 
submitted to the FDA for prior approval, 43% of them believed that only completely safe drugs 
could be promoted directly to consumers, 22% of them believed that promoting of drugs with 
serious side effects had been banned, and 21% of them thought that only extremely effective 
drugs could be marketed directly to consumers. However, given that all of these statements are 
untrue, the results imply that there is a possibility that consumers may have a serious 
misunderstanding regarding the DTCA's regulatory context. In particular, as to minorities they 
were more misinformed about the DTCA regulation than were white respondents (Bell et al., 
1999). Bell et al. (1999) note that many consumers hold inaccurate beliefs regarding the 
regulation of DTCA and this false faith could increase susceptibility to DTCA, because 
consumers with erroneous assumptions are more likely to act on them. 
The statements employed in previous research on public's knowledge of DTCA 





employed in the current research. This research employed various statements to measure 
consumers' DTCA regulatory knowledge, which were borrowed from the FDA's consumer 
education webpage. In that regard, the findings of this research provide invaluable consumer 
education and public health implications, which is a unique contribution of the current research. 
It may be both the FDA's and pharmaceutical marketers' responsibility to inform consumers 
about critical aspects of DTCA regulation. To help consumers make better prescription 
decisions, both the FDA and pharmaceutical marketers should exert organized efforts to inform 
consumers regarding the regulatory context of DTCA through various methods. In the long term, 
pharmaceutical marketers should communicate risk information openly and accurately with 
consumers. In particular, they need to provide much attention to health risks of the medicine. 
From the FDA's perspective, the agency can fully educate the role of promotional 
materials or prescription drug brands, the role of drug evaluations, and the need for consumers to 
cooperate with health care professionals (Wilkes et al., 2000). Furthermore, health care 
professionals can also develop a systematic media literacy program to educate consumers about 
the promotional nature of DTCA as well as the regulatory context of DTCA (Bell et al., 1999; 
Wilkes et al, 2000) to promote important health care marketplace persuasion knowledge. 
Moreover, the public needs to be informed about the limitations of DTCA placed on its 
regulation. To do so, Bell et al. (1999) suggest that the development of a media literacy program 
that teaches about the nature of pharmaceutical advertisers' persuasive strategies with 
cooperation on the part of the FDA, health care professionals, and public health organizations 
will contribute to public health. Importantly, health consumers themselves should exert efforts to 





health information regarding both benefits and risks of medical remedies. For true health 
consumerism, it is also individuals' responsibility to behave actively as health consumers. 
In this regard, the Pharmaceutical Research and Manufacturers of America’s (PhRMA) 
(2009), an organization representing pharmaceutical companies, industry guidelines for DTCA 
outline an important premise that: 
DTC advertising of prescription medicines can benefit the public health by increasing awareness about 
diseases, educating patients about treatment options, motivating patients to contact their physicians and 
engage in a dialogue about health concerns, increasing the likelihood that patients will receive appropriate 
care for condition that are frequently under-diagnosed and under-treated, and encouraging compliance with 
prescription drug treatment regimens. 
   
In the above voluntary guidelines, an important goal of DTCA is well-illustrated. That is, 
DTCA should encourage consumers to get proper medical treatment based on proper health 
education. Despite potential health risks of the drug, consumers should have a chance to discuss 
with their doctors about the advertised drug, in order to find out the best medical remedies to 
manage their own health issues. The current research adds that consumers also need to be 
educated about the FDA’s regulatory role for DTCA to better cope with DTCA health 
information, especially risk disclosure. 
In closing this section, there has been a long severe controversy regarding the role of 
mass media between its health promotion and worsening functions (Wallack, 1989, 1990). 
Proponents believe that mass media can provide the right health information to the right people 
in the right way at the right time, whereas critics argue that mass media could be a barrier to 
health education because media institutions are supposed to be driven by profit (Wallack, 1989). 
However, one thing for sure is that mass media play an important role in communicating relevant 





preventive and remedial health behaviors (e.g., McGuire, 1984; O’Keefe & Reid-Nash, 1986).  
However, despite the potential contribution of DTCA to public health, the literature has 
ignored how risk information can be better communicated from the consumer perspective (Hoy 
& Andrews, 2004). Stewart and Martin (2004) note that “regulation of marketing communication 
should not be less consumer centric” (p. 190). Although this idea is not original, the complexity 
of consumer information processing calls for research that measures consumer response to 
disclosure information. Considering the findings of the current research, it is clear that one needs 
to consider how consumers actually perceive health risks of the drug and utilize such information 
in their health decision making. Among various consumer side-factors, the current research 
especially explored the potential role of DTCA regulatory knowledge as pharmaceutical 
marketplace persuasion knowledge. Organized efforts to improve consumer DTCA regulatory 
knowledge through various education programs could contribute to public health through 





CHAPTER 6: LIMITATIONS AND FUTURE RESEARCH RECOMMENDATIONS 
 As with most studies, several important limitations of the study and avenues for future 
research warrant mention. First, although the current research employed a professional online 
survey company to reach a relatively representative US adult sample, caution should be taken on 
generalizing the results to other contexts, because the respondent recruiting method was a 
convenience sampling in nature. More often than not, it is not easy for researchers to reach a 
fully US representative adult sample due to the limited time and resources. Nevertheless, one 
alternative remedy to reduce potential response biases in the data of this study was the utilization 
of random assignment (Kerlinger & Lee, 2004; Shadish et al, 2002; Wimmer & Dominick, 
2006). The survey software, Qualtrics, allowed the researcher to randomly assign respondents to 
each treatment condition. Further, to counterbalance any order effects in multiple choice 
questions, the researcher also randomized choice presentation orders for major dependent 
variables (e.g., recognition). However, future research needs to examine various contexts and 
utilize more representative populations to replicate and extend the current research findings.  
Second, when applying the findings of this research to other cultural contexts, careful 
considerations should be exerted. Currently, DTCA is allowed in only two countries in the world 
(Royne & Myers, 2008): the US and Newzealand. Although many countries currently consider 
the legalization of the DTCA practice (e.g., South Korea), most DTCA studies have been 
conducted exclusively in the US and Newzealand contexts. In this regard, the interpretation of 
the current research findings should be limited to the US context because the regulatory 
environment and research participants were based on the US context.  





information processing mechanisms across different cultural contexts. For instance, different 
styles of risk appraisal or avoidance of uncertainty could influence consumer processing of risk 
disclosure in DTCA differently. For instance, it has been well documented that collectivistic and 
individualistic cultures have their preferred regulatory orientation. Collectivists are more likely 
to be prevention-focused and individualists are more likely to be promotion-focused (Lee, Aaker, 
& Gardner, 2000). This implies that consumers’ receptivity of risk disclosure in DTCA or 
medical product advertising can be different across different cultural schemas. In a similar vein, 
Hoy and Andrews (2004) note that different risk disclosure presentation modalities may work in 
different ways across distinct countries. Further, they suggest that risk disclosure research on 
cultural differences can contribute to global consumer interests (Hoy & Andrews, 2004). The 
current research adds that such program of research can expand the scope of DTCA risk 
disclosure research by incorporating global health consumerism perspectives, because health 
care empowerment is increasingly receiving global attention. 
Third, in terms of the manipulation of risk disclosure prominence, there could be various 
considerations and alternatives. According to the FDA’s (2009) draft guidance for risk 
communication in DTCA, this research employed several widely used message execution factors 
to highlight risk disclosure. However, risk disclosure prominence can be conceptualized and 
operationalized in many ways. More often than not, the concept of fair balance is defined in 
terms of the relative amount of benefit and risk information (Huh & Cude, 2004; Sheehan, 2007; 
Macias et al., 2007). Some studies define prominence in terms of relative placement and 
modality of risk information (Davis, 2010). Typographical devices such as box-warnings are also 





research, to reflect the FDA’s (2009) current thought on fair balance in DTCA, several message 
factors were utilized simultaneously to probe consumers’ net impression other than their 
reactions to particular aspects of the ad. Future research can examine risk disclosure prominence 
though different conceptualizations and operationalizations. 
 Fourth, this research did not pay much attention to the interactive roles of benefit and risk 
information on consumer response to the ad, because the focus of research was on risk disclosure 
prominence. However, an additional analysis revealed that despite the exactly equivalent content 
and format for the uses of the drug across different test ads, the perceived prominence of the uses 
of the drug (as a confounding check) was slightly different, depending on varying risk disclosure 
prominence levels. One intriguing speculation would be that consumer perception could be 
affected by the interactive influence of benefit and risk information. In the additional analysis, 
the researcher found that as risk disclosure prominence increased, perceived prominence of drug 
use information decreased, though it was not statistically significant. One future research avenue 
will be examining the interactive effects of benefit and risk information presentation formats on 
consumers’ perception. In line with this, the FDA (2009) is concerned about overall impression. 
However, what is lacking in the FDA’s guidance for risk communication is the recognition that 
surface-level fair balance cannot secure intended risk disclosure outcomes. Consumer perception 
will be largely context-driven. A program of research on this research inquiry is warranted. 
Fifth, the present research did not address the content effects. However, the content of 
risk disclosure itself as well as its format can influence consumer response to the ad. It has been 
known that perceived severity of health risks affects consumers’ health behavior (Carpenter, 





that prescription drugs can be purchased only through prescription from health professionals, it is 
implied that prescription drugs’ health risks may be more serious than those of over-the-counter 
drugs that can be purchased without prescription. However, different therapeutic categories and 
brands may have different health risks and therefore the effects of risk disclosure will be affected 
by the health risk content itself. Moreover, it is possible that the format and content of risk 
disclosure may interact from one another. Researchers may need to differentiate between the 
effects of the content and format of DTCA. 
 Sixth, this study examined print media type DTC ads even though it was presented in an 
online survey through the Internet. A number of branded DTCA websites present information 
about the drug including benefit and risk information in a similar manner with print DTCA. 
However, various media interfaces have unique technological characteristics. A body of research 
has examined branded prescription drug websites to examine the content of DTCA and their 
message appeals (e.g., Huh & Cude, 2004; Sheehan, 2007; Wymer, 2010). Such interactive 
media may utilize various information provision modalities such as voice and video (Davis, 
2010). In line with this, different media interfaces call for different consideration of risk 
disclosure presentation (Hoy & Andrews, 2004). For instance, interactivity could be considered 
an important factor affecting prominence (Cauberghe & Pelsmacker, 2010). Applying to the 
DTCA context, the Internet or mobile devices may lead researchers to conceptualize and 
operationalize risk disclosure prominence differently. However, little research has examined the 
risk disclosure prominence effects in the rich media contexts. Future research can address how 
the different media contexts relate to varying consumer information processing mechanism of 





 Seventh, although the current research employed a perceived attention measure to assess 
consumer attention to risk disclosure in DTCA, a concern could be raised about the self-report 
single-item measure for the construct. As discussed in the method section, there is a practical 
utility of perceived attention approach. Nevertheless, a more reliable measure will be physio-
psychological approaches. In addition, regarding the timing of measuring perceived attention, 
there could also be a concern about demand characteristics, because some manipulation checks 
of risk disclosure prominence that may signal health risks of the drug were positioned before the 
perceived attention measure. Due to a potential discrepancy between objective and subjective 
measures, a more objective and accurate measure to assess to what information a person attended 
may be via eye-tracking. For instance, when subjects claim to have looked at risk disclosure 
information through self-reported answers, it is possible that they did not look at all. This 
indicates that subjective self-report attention measures may have limitations and therefore could 
serve only as a proxy measure of actual attention. Researchers should pay careful attention to 
interpret the results when using subjective measures. 
 As an alternative for future research, eye tracking approach is a technique whereby 
subjects’ eye movements are measured so that the researcher understand where an individual is 
looking at any given time, and the sequence in which their eyes are shifting from one location to 
another (Poole & Ball, 2005). This method has been used in the advertising literature to 
determine what advertisement designs attract the greatest attention (Lohse, 1997) and to 
determine if Internet users pay attention to banner advertising on websites (Albert, 2002). Of 
course, as with every experimental methods, eye tracking does not represent a perfect approach 





mind when applying the method. Among others, subjects should have well-defined tasks to carry 
out so that their eye movements can be appropriately attributed to actual cognitive processing 
(Poole & Ball, 2005). That is, eye movements per se cannot guarantee accurate cognitive 
processing measurement. Eye tracking researchers can employ various methodological devices 
in combination to address this limitation (Poole & Ball, 2005). 
 Eighth, the measurement of DTCA regulatory knowledge may have limitations. The most 
common way to measure knowledge has been multi-item scales¸ having two to four items (e.g., 
Beatty & Smith, 1987; Park et al., 1994). Although good reliabilities have been reported for such 
multi-item scales, they were all essentially ad hoc, generated for the first time for the purpose at 
hand, and were not validated or employed in another study (Flynn & Goldsmith, 1999). This is 
also the case in the current research. Despite the conceptual originality and its public education 
and health implications, the multi-item measurement scale of DTCA regulatory knowledge in the 
current research shows low reliability (Chronbach’s α = .29). Statistically speaking, when 
true/false type test answers are coded as dummy variables to form a composite score to represent 
varying knowledge levels, it is likely that the internal consistency value (i.e., Cronbach’s alpha) 
for the categorical items is low. For instance, House et al. (2004) measured consumers’ objective 
knowledge about the facts and issues concerning genetic modification in food production in 
order to examine its effects on consumers’ willingness to accept genetically modified foods, and 
found significant knowledge effects. They employed four-item true/false type questions. 
However, its measurement scale reliability was relatively low (i.e., Cronbach’s α= .54).  
In this case, a more appropriate description for such type of measurement items may be 





descriptive statistics for each item. Nevertheless, it is suggested that future research develops a 
reliable measurement scale for DTCA regulatory knowledge so that some degree of 
measurement standardization in DTCA research can be attained. At this moment in time, 
considering that there is a dearth of research on this construct in the DTCA literature, the 
exploratory approach to measuring DTCA regulatory knowledge may be justified. 
 Ninth, the subjects of the current research consists of higher percentage of males (63.6%) 
than that of females (36.4%). This could be a lack of representation of the profile of actual users 
of Rx anti-depressant. Future research may employ a more representative sample profile to better 
represent the current antidepressant users. However, it is noteworthy that according to CDC, in 
terms of gender, during 2007-2010 5.3% of male respondents reported that they have used 
antidepressants, while 11.9% have used antidepressants in past 30 days (CDC, National Center 
for Health Statistics. Health, United States, 2012). The percentage of male users have rapidly 
increased from 1.2% during 1988-1994, to 4.4% during 1999-2002, and to 5.3% during 2007-
2010. Considering the educational role of DTCA, the current research finding may provide 
insight into potential antidepressant users’ (i.e., males) response to antidepressant DTCA. 
 Tenth, the sample of the current research represents general adult consumers rather than 
individuals who have been diagnosed with the disease. Approximately 30% of subjects reported 
having been diagnosed with mental depression. This could be justified when considering that the 
major purpose of DTCA is not only to increase consumer generated prescription volume but also 
provoke and facilitate an initial self-diagnosis from DTC ads (Davis, 2006). In the current 
research, given its focus on health risk information in DTCA, a list of questions were given to 





prescription drug, including personal experience (48.5%), family (38.3%), relatives (35.2%), 
your circle of friends (31.1%), your circle of neighbors (13.6%). These results show that 
approximately half of the subjects have experienced any health risks from the use of prescription 
drugs and at least 30% of them have indirect experience with health risks regarding prescription 
drug use. While individuals with depression diagnosis experience could be an appropriate sample 
of antidepressant DTCA research, given the focus of research on risk disclosure processing and 
the role of DTCA regulatory knowledge, the use of the current sample seems plausible. Future 
research can employ individuals with direct depression experience to examine how DTCA 
regulatory knowledge and prominence work differently among such consumers. 
 Eleventh, future research may need to provide basic information about clinical depression 
in the research instrument. According to research, there was significant increase in the proportion 
of people recognizing depression in the vignette during 1998-2004 in Australia. For instance, 
compared with 1998, in 2004 mental health literacy including depression recognition increased 
considerably (Goldney, Fisher, Dal Grande, & Taylor, 2005). In a similar vein, the current 
research subjects show a reasonably good understanding of what clinical depression is through 
perceived familiarity, subjective knowledge, and perceived importance. Nevertheless, it is 
possible that many US consumers may not be able to clearly differentiate between clinical 
depression and short periods of sadness. Future research instruments could clarify what clinical 
depression is to provide a foundation to research participants. 
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Appendix A: Survey Questionnaire 
Thank you for your willingness to participate in this study. Ilwoo Ju (Doctoral Candidate) at the 
University of Tennessee is the primary investigator of this study, and is attempting to understand the use 
of health information among adults.  
 
There are no anticipated risks for study participants. However, if you do not wish to answer a question, 
you may skip it. Participation is voluntary. If you wish to quit the project at any time, you can simply 
close the survey. 
 
If you have questions about the study or the procedures, you may contact the primary researcher Ilwoo Ju 
by mail at 401 Student Services Building, Knoxville, TN 37996, by phone at (865) 318-4004, or by e-
mail at iju@utk.edu. If you have questions about your rights as a participant, contact Brenda Lawson in 
the Office of Research & Engagement at (865) 974-7697 or blawson@utk.edu. 
 
The information you provide will be anonymous. You will not be identified individually at any stage of 
the study. The data and your informed consent will be stored in a secured place (the University of 
Tennessee Communication College Doctoral Office) during the analysis for 3 years and will be destroyed 
afterwards. You must be age 18 or older to participate. 
 







The primary focus of this survey is on your thoughts and feelings about health issues in 
general. Please read carefully and answer the following questions.  
 










Q2) How familiar would you say you are with the issue of clinical depression?  
not at all 
familiar 
  moderately 
familiar 
  very familiar 
       
 
Q3) How knowledgeable would you say you are about clinical depression?  
not at all 
knowledgeable 
  moderately 
knowledgeable 
  very 
knowledgeable 
       
       
Q4) How important is the issue of clinical depression to you?  
 
not at all 
important   
moderately 
important   
very 
important 
       
 
Q5) Have you ever been diagnosed with clinical depression?   
 
Yes _____ No_____   
 
Q6) In the following questions, please report your opinions about prescription drug advertising. 
      
Note: “Prescription drug” refers to a drug you can get only with a doctor’s prescription.  
 











       
 











       
 
6-3) We can depend on getting the truth in most prescription drug advertising. 





disagree disagree disagree agree agree 
       
 











       
 











       
 











       
 











       
 











       
 
Q7) For each statement, please check a box to report your beliefs about prescription drug 
advertising. 
 
     Note: “Prescription drug” refers to a drug you can get only with a doctor’s prescription. 
 
7-1) The FDA bans consumer-directed ads for prescription drugs that have serious health risks. 
Yes______   No______    Don’t know ______ 
 
7-2) The FDA requires drug companies to use hard-to-understand medical language in 
prescription drug ads directed to consumers.  
Yes______   No______    Don’t know ______ 
 
7-3) The FDA works with drug companies to create prescription drug ads directed to consumers.  





         
7-4) The FDA approves prescription drug ads before they are seen by the public.  
Yes______   No______    Don’t know ______ 
 
7-5) The FDA regulates the design of prescription drug ads directed to consumers.  
Yes______   No______    Don’t know ______ 
 
7-6) The FDA conducts research to examine consumer attitudes and behaviors toward 
prescription drug advertising. 
Yes______   No______    Don’t know ______ 
 
Q8) Please report your past experiences with prescription drugs.  
 
Q8-1) Have you ever experienced adverse reactions after taking a prescription drug?  
Yes______   No______    Don’t know ______ 
 
Q8-2) Has anyone in your family experienced prescription drug adverse reactions?  
 Yes______   No______    Don’t know ______ 
  
Q8-3) Has anyone among your relatives experienced prescription drug adverse reactions? 
Yes______   No______    Don’t know ______ 
 
Q8-4) Has anyone within your circle of friends experienced prescription drug adverse reactions?   
 Yes______   No______    Don’t know ______ 
 
Q8-5) Has anyone within your circle of neighbors experienced prescription drug adverse 
reactions?   
 Yes______   No______    Don’t know ______ 
 
Q9) Please check a box to indicate your agreement with the following statement.  
 
“If someone hasn’t experienced prescription drug adverse reactions by now, he or she is not 












       
Q10) In the past six months, how often have you seen, read, or heard instances where the health 





 never   occasionally 
  very often 
Television news, 
documentaries, and current 
affairs. 
       
 
Television entertainment 
programs (e.g., soap operas, 
sitcoms, drama, movies). 
       
Articles in newspapers and 
magazines.        
Non-advertising information 
from the Internet.        
 
 
Imagine that you feel like you may be 
clinically depressed and have just come 
across the webpage for a new 
prescription medicine for depression.  
 
Please read the ad as you would if you 







The following questions are about the ad you just saw. Please read and answer them 
carefully.  
  
Q11) The ad presented information about the uses and health risks of Luminexell. Please check a 
box that best represents your thoughts.  
 
The ad presented the uses of Luminexell more prominently than its health risks  
The ad presented the health risks of Luminexell more prominently than its uses  
The ad presented the uses and health risks of Luminexell equally in terms of prominence  
  
 
Q12) How prominently do you think the ad presented the uses of Luminexell?  
 











































Q13) How prominently do you think the ad presented the health risks of Luminexell? 
 












































      














It was easy to find the 
information about the health 






















It was easy to focus on the 
information about the health 


























I liked the way the ad 
presented the information 
























Q15) How much attention did you pay to the information about the health risks of Luminexell? 
no attention   moderate attention 
  great attention 
       
 
Q16) The ad presented the health risks of Luminexell. In the box below, please write all the 






Q17) How easy do you feel it was to recall the health risks of Luminexell presented in the ad? 
 
extremely 
easy      
extremely 
difficult 
       
 
Q18) Which of the following were presented in the ad as the health risks of Luminexell? Please 
check all that apply. 
 
 Seizures   
 Decrease in white blood cells 
 High fever 
 Lightheadedness upon standing 
 Trouble swallowing 
 Rigid muscles 
 Impairment in motor skills 
 Insomnia  
 Increased heart rate 
 Abnormal facial movements 
 
Q19) Given the above check list, how easy do you feel it was to recognize the health risks of 
Luminexell presented in the ad? 
 






       
Q20) Imagine that you take Luminexell to treat clinical depression. Then I would like you to 
think of people your own age and sex who also take the drug. Compared with other people 
your age and sex, how would you rate your chances of experiencing the adverse reactions of 
Luminexell?   
far less        
likely 
less                
likely 





slightly         
more likely 
more              
likely 
far more      
likely 
       
 





    50-50 
chance 

























   
Q22) What do you believe is the chance that the average person your age and sex will 




    50-50 
chance 


























Q23) How much personal control do you feel you have over the chances of experiencing the 




    moderate 
control 
























       
 
 
Q24) If you experience the adverse reactions of Luminexell, how serious do you believe they 
would be?  























Q25) How safe would you say Luminexell is? 





























Q26) If you were to use a prescription drug for treating depression, how likely would you be to 
choose Luminexell? 
 





























Q27) Imagine that you take Luminexell to treat depression. For each statement, please check a 















I would like to learn more about the 















When I come across other useful 
information about the health risks 
















I would like to use various media 
sources to get more information 

















Q28) Please check your gender.  Female_____  Male_____ 
 






Q30) What is your ethnic background?    
 
White, not Hispanic _____    Hispanic, of any race _____   Black, not Hispanic _____ 
Asian or Pacific Islander ________   American Indian, Eskimo, or Aleut _______  
Other (Please specify) _____    
 
 
Q31) What is the highest level of education you received? 
 
1. Did not finish high school 
2. Completed high school but no college education 
3. Some college education but no degree 
4. Associate’s degree (examples:  AA, AS) 
5. Bachelor’s degree (examples:  BA, BS) 
6. Attended graduate school but no degree 
7. Master’s degree (examples: MA, MBA) 
8. Professional degree (examples: JD, MD) 
9. Doctorate degree (examples: PhD, EdD) 
 
Q32) What is your annual household income? 
 
1. lower than $25,000     
2. $25,000 ~ $49,999 
3. $50,000 ~ $74,999    
4. $75,000 ~ $99,999 
5. $100,000 ~ $149,999   
6. $150,000 or higher 
 
Q33) What type of device did you use to participate in this survey? 
 
1. Smartphone 
2. Tablet PC 
3. Laptop computer 
4. Desktop computer  
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